var title_f11_4_11328="Algorithm Oligomenorrhea";
var content_f11_4_11328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Approach to oligomenorrhea in adolescents",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 639px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Depot medroxyprogesterone acetate.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11328=[""].join("\n");
var outline_f11_4_11328=null;
var title_f11_4_11329="Histology lung 2A answer";
var content_f11_4_11329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary coccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of a hematoxylin and eosin-stained section of lung tissue (x400) shows a large spherule of Coccidioides immitis, which contains many endospores. Identification of this organism may also be made by fungal culture on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11329=[""].join("\n");
var outline_f11_4_11329=null;
var title_f11_4_11330="Renal pathology test: Case presentations";
var content_f11_4_11330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal pathology test: Case presentations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11330/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11330/contributors\">",
"     Helmut G Rennke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11330/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11330/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11330/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/4/11330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 3, 2007.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the following cases is associated with a renal biopsy most consistent with the clinical presentation. The first histology picture serves as an \"unknown\" for the reader to evaluate. The correct answer may subsequently be obtained by clicking the mouse on the unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 25 year-old man presents with a history of \"red urine\" and swelling for several days. Physical examination and laboratory analysis are notable for hypertension, periorbital swelling, an elevated plasma creatinine concentration, and red cell casts on urinalysis. Findings on renal biopsy are consistent with which one of the following light micrographs shown in panels A and B? Question: (",
"    <a class=\"graphic graphic_picture graphicRef65290 \" href=\"UTD.htm?15/54/16232\">",
"     picture 1",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef72992 \" href=\"UTD.htm?17/9/17560\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 68 year-old woman complains of swelling of the ankles for the last five months. The plasma creatinine is 3.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (283",
"    <span class=\"nowrap\">",
"     &micro;mol/L);",
"    </span>",
"    one year ago, it was 1.8",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Urinalysis reveals hematuria without casts; the urine total protein to creatinine ratio is 5.2. Renal biopsy, including light, immunofluorescence, and electron microscopy, is performed. No staining with Congo red is observed. What is the diagnosis? Question: (",
"    <a class=\"graphic graphic_picture graphicRef51987 \" href=\"UTD.htm?5/46/5866\">",
"     picture 3",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef63777 \" href=\"UTD.htm?7/5/7258\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CASE 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;An 18 year-old man is referred for the evaluation of persistent hematuria, detected on a screening medical evaluation. The patient was first noted to have hematuria at the age of 15; no evaluation, however, was performed at that time. There is no history of gross hematuria, but the maternal grandfather had renal failure. No other information is available. The urinalysis is notable for microscopic hematuria. Which of the following findings on immunofluorescence and electron microscopy are most consistent with this presentation? Question: (",
"    <a class=\"graphic graphic_picture graphicRef75343 \" href=\"UTD.htm?24/9/24727\">",
"     picture 5",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef54576 \" href=\"UTD.htm?26/5/26711\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CASE 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 22 year-old woman presents with the acute onset of renal failure and hypertension one month after giving birth. Her pregnancy was uncomplicated, the delivery was unremarkable, and she has no previous history of renal disease or hypertension. Urinalysis reveals hematuria and proteinuria but no casts. Findings on renal biopsy are consistent with which one of the following light micrographs shown? Question: (",
"    <a class=\"graphic graphic_picture graphicRef66302 \" href=\"UTD.htm?1/4/1095\">",
"     picture 7",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef78114 \" href=\"UTD.htm?5/53/5975\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CASE 5",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 22 year-old intravenous drug addict has a four year history of insulin-dependent diabetes mellitus. He is referred for the evaluation of the onset of swelling for one month. Physical examination reveals marked peripheral edema but no retinopathy. Other than a few red cells, microscopic analysis of the urine is unremarkable; the urine total protein to creatinine ratio is 8.0. What is the diagnosis? Question: (",
"    <a class=\"graphic graphic_picture graphicRef57094 \" href=\"UTD.htm?31/41/32406\">",
"     picture 9",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef68860 \" href=\"UTD.htm?34/34/35366\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CASE 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 22 year-old nonsmoking man presents with a several month history of malaise, fatigue, myalgias, and arthralgias. One week ago, he noticed blood-streaked sputum after coughing. Physical examination is unremarkable. Laboratory analysis reveals a plasma creatinine concentration of 2.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (186",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    and numerous red and white cells but no casts are noted on urinalysis. Which of the findings on renal biopsy and peripheral blood smear are most consistent with this presentation? Question: (",
"    <a class=\"graphic graphic_picture graphicRef79759 \" href=\"UTD.htm?12/18/12585\">",
"     picture 11",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef55553 \" href=\"UTD.htm?13/16/13577\">",
"     picture 12",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CASE 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 78 year-old male is referred for the evaluation of worsening renal dysfunction. The patient has a history of type 2 diabetes mellitus for five years, and a long-standing history of peripheral vascular disease and hypertension. At a visit two months ago, his BUN and creatinine were 22",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (159",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    respectively. Today, during a routine visit, the respective values are 58",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (21",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and 6.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (530",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    He denies any recent history of illness, change in medication, or use of analgesics. The physical examination is notable for a blood pressure of",
"    <span class=\"nowrap\">",
"     140/95",
"    </span>",
"    mmHg. The urinalysis is bland. Renal biopsy is consistent with which of the following light micrographs? Question: (",
"    <a class=\"graphic graphic_picture graphicRef66459 \" href=\"UTD.htm?8/6/8296\">",
"     picture 13",
"    </a>",
"    ). Answer: (",
"    <a class=\"graphic graphic_picture graphicRef78805 \" href=\"UTD.htm?10/22/10600\">",
"     picture 14",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7251 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11330=[""].join("\n");
var outline_f11_4_11330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CASE 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CASE 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CASE 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CASE 5",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CASE 6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CASE 7",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7251\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7251|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/54/16232\" title=\"picture 1\">",
"      Histology case 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/9/17560\" title=\"picture 2\">",
"      Histology case 1 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/46/5866\" title=\"picture 3\">",
"      Histology case 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/5/7258\" title=\"picture 4\">",
"      Histology case 2 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/9/24727\" title=\"picture 5\">",
"      Histology case 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/5/26711\" title=\"picture 6\">",
"      Histology case 3 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/4/1095\" title=\"picture 7\">",
"      Histology case 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/53/5975\" title=\"picture 8\">",
"      Histology case 4 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/41/32406\" title=\"picture 9\">",
"      Histology case 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/34/35366\" title=\"picture 10\">",
"      Histology case 5 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/18/12585\" title=\"picture 11\">",
"      Histology case 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/16/13577\" title=\"picture 12\">",
"      HIstology case 6 with answer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/6/8296\" title=\"picture 13\">",
"      Histology case 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/22/10600\" title=\"picture 14\">",
"      Histology case 7 with answer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_4_11331="Patient information: When your lungs fill with fluid (The Basics)";
var content_f11_4_11331=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85803\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/49/28439\">",
"         Food labels can be tricky",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/63/20474\">",
"          Heart failure action plan - page 1",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/48/32522\">",
"           Heart failure action plan - page 2",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/43/16050\">",
"            Pitting edema",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/41/36499\">",
"         Patient information: Medicines for heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/61/39890\">",
"         Patient information: Low sodium diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: When your lungs fill with fluid (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7574115\">",
"      <span class=\"h1\">",
"       Why do your lungs fill with fluid when you have heart failure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When you have heart failure, your heart does not pump as well as it should. It does not squeeze or fill as well as before. That means that the organs in your body do not get as much blood as they used to, especially when you exercise. As a result, the heart struggles to keep blood moving, but it lags behind. When that happens, fluid builds up in the body.",
"     </p>",
"     <p>",
"      Fluid can build up in the feet and ankles. That&rsquo;s why people with heart failure sometimes get swollen ankles (",
"      <a class=\"graphic graphic_picture graphicRef61706 \" href=\"UTD.htm?15/43/16050\">",
"       picture 1",
"      </a>",
"      ). Fluid can also build up in the lungs. That&rsquo;s why people with heart failure sometimes have trouble breathing.",
"     </p>",
"     <p>",
"      Having fluid in the lungs can be life-threatening. Fluid in the lungs is the number 1 reason people with heart failure end up in the hospital. But it is often avoidable.",
"     </p>",
"     <p>",
"      To keep heart failure from getting worse, and to keep yourself breathing as well as possible, 1 of the most important things you can do is to keep your body from holding onto extra fluid. That&rsquo;s why it is so important to take your medicines for heart failure and to limit how much salt you eat. These 2 things are explained more below.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7574147\">",
"      <span class=\"h1\">",
"       Why are medicines for heart failure so important?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Medicines to treat heart failure can help you feel better and live longer. They can help keep fluid out of your lungs and help you breathe better. Missing just 1 dose of medicine can make a big difference in how you feel.",
"     </p>",
"     <p>",
"      One type of heart failure medicine is a &ldquo;diuretic&rdquo; (sometimes called a water pill). A diuretic helps the body get rid of extra salt and fluid. That way fluid is less likely to build up in the ankles, belly, or&mdash;most importantly&mdash;the lungs.",
"     </p>",
"     <p>",
"      Some people skip their diuretic because they do not like having to go to the bathroom all the time. But if you are going to the bathroom a lot to urinate, that means the medicine is working. It means your lungs are less likely to fill with fluid.",
"     </p>",
"     <p>",
"      Ask your doctor or nurse which of your medicines is a diuretic. The most commonly used diuretic is called &ldquo;",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?12/14/12518?source=see_link\">",
"       furosemide",
"      </a>",
"      .&rdquo; Its brand name is Lasix&reg;.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7574162\">",
"      <span class=\"h1\">",
"       Why is it important to limit salt?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is hard to imagine, but eating just 1 or 2 meals with too much salt can make you very sick. That&rsquo;s because eating a lot of salt causes fluid to build up&mdash;sometimes in your lungs.",
"     </p>",
"     <p>",
"      When people hear that they need to cut down on salt, they think that means they should not use the saltshaker at the table. It is important to avoid the saltshaker. But most of the salt you eat does not come from salt you add at the table or even in your cooking. Most of the salt people eat comes in canned and packaged foods.",
"     </p>",
"     <p>",
"      If you are eating something that comes in a box, can, or bag, chances are it has a lot of salt. To find out, you will need to check the label and pay attention to how many portions you have. Salt is labeled as &ldquo;sodium&rdquo; on food labels (",
"      <a class=\"graphic graphic_figure graphicRef53229 \" href=\"UTD.htm?27/49/28439\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7574196\">",
"      <span class=\"h1\">",
"       Are there warning signs that my lungs are filling with fluid?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, often there are! When heart failure is getting worse, the body gives off the following clues:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Sudden weight gain",
"       </li>",
"       <li>",
"        Increased swelling in the feet, ankles, legs, or other parts of the body",
"       </li>",
"       <li>",
"        Increased tiredness or trouble breathing",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you spot 1 or more of these signs, you should take action. Your body is telling you that things are starting to go wrong.",
"     </p>",
"     <p>",
"      You and your doctor or nurse can write up an &ldquo;action plan.&rdquo; The action plan will tell you what to do if you spot signs that your heart failure is getting worse (",
"      <a class=\"graphic graphic_figure graphicRef72459 \" href=\"UTD.htm?19/63/20474\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef75501 \" href=\"UTD.htm?31/48/32522\">",
"       figure 3",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7574246\">",
"      <span class=\"h1\">",
"       Why must I weigh myself every day?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Water is heavy, so your weight will go up if your body is holding onto extra fluid. If you weigh yourself every day, you will know right away when fluid starts to build up. A sudden weight gain can be an early sign that your heart failure is getting worse. If you spot a weight change, you can take steps to keep the problem from getting worse.",
"     </p>",
"     <p>",
"      Here&rsquo;s what you should do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Weigh yourself every morning after you urinate and before you eat or drink.",
"       </li>",
"       <li>",
"        Use the same scale and wear roughly the same amount of clothing (or wear nothing) every time you weigh yourself.",
"       </li>",
"       <li>",
"        Keep a chart near the scale and WRITE DOWN your weight every day.",
"       </li>",
"       <li>",
"        Each time you write down your weight, check if the number has gone up from the day before and the week before. If so, follow your action plan.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For most people, a weight gain of 2 to 3 pounds in 1 day is cause for concern. Gaining 5 pounds in 1 week is also a bad sign. Weight gains like these are signs that the heart is working extra hard to move that fluid around.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7574261\">",
"      <span class=\"h1\">",
"       Why must I check for swelling every day?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you become swollen, that&rsquo;s another sign that your body is holding onto extra fluid. If any part of your body looks more swollen than usual, don&rsquo;t ignore it. Even if you do not feel any differently than usual, this is a sign that your heart is having more trouble.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7574276\">",
"      <span class=\"h1\">",
"       Follow an action plan!",
"      </span>",
"      &nbsp;&mdash;&nbsp;Now that you know how to spot the clues that your heart failure is getting worse, you need to know what to do if you notice those changes. Ask your doctor or nurse to fill out an action plan with you. An action plan is a set of instructions on what to do if you have changes in symptoms.",
"     </p>",
"     <p>",
"      Take your action plan seriously. Keep it on the refrigerator or someplace where you can easily find it. If you follow your action plan closely, you might be able to avoid a trip to the hospital or know when it is important to call an ambulance to go to the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7574291\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=see_link\">",
"       Patient information: Medicines for heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       Patient information: Low sodium diet (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/4/11331?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85803 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11331=[""].join("\n");
var outline_f11_4_11331=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7574115\">",
"      Why do your lungs fill with fluid when you have heart failure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7574147\">",
"      Why are medicines for heart failure so important?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7574162\">",
"      Why is it important to limit salt?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7574196\">",
"      Are there warning signs that my lungs are filling with fluid?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7574246\">",
"      Why must I weigh myself every day?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7574261\">",
"      Why must I check for swelling every day?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7574276\">",
"      Follow an action plan!",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7574291\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85803\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/49/28439\">",
"      Food labels can be tricky",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/63/20474\">",
"       Heart failure action plan - page 1",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/48/32522\">",
"        Heart failure action plan - page 2",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/43/16050\">",
"         Pitting edema",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_4_11332="Case illustrating blood glucose monitoring in type 2 diabetes";
var content_f11_4_11332=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Case illustrating blood glucose monitoring in type 2 diabetes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11332/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11332/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11332/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11332/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11332/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11332/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/4/11332/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following case illustrates the value of blood glucose monitoring in patients with type 2 diabetes, depending upon the time, treatment, and stage of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 56-year-old woman who is a clothing sales assistant presents with thirst, fatigue, and a vaginal yeast infection. She is 5 feet, 4 inches (163 cm) tall and weighs 265 lbs (120 kg). A random blood glucose value is 460",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (25.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and her hemoglobin A1C (HbA1c) value is 11.4 percent. She eats a diet high in fat and refined carbohydrate, and she exercises little. She watches TV for several hours nearly every evening, during which time she often eats two or three sugar-covered donuts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate initial management is to arrange for education about diabetes, in the form of written material, videos, and follow-up in an education and support group with other obese patients with type 2 diabetes; advise her to modify her eating habits (reducing caloric intake and eliminating refined carbohydrate) and encourage her to walk on a treadmill for at least 30 minutes at least five evenings a week at home. She should also be asked to measure fasting blood glucose every morning.",
"   </p>",
"   <p>",
"    Her thirst, fatigue, and vaginal infection subside soon thereafter. During the next three weeks, her blood glucose values (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    during a typical week are as follows:",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Comments",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; breakfast",
"   </p>",
"   <p>",
"    Mon &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;265 (14.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Exercised on treadmill",
"    <br/>",
"    Tue &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;184 (10.2) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Exercised on treadmill",
"    <br/>",
"    Wed &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 175 (9.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No exercise, 2 donuts!",
"    <br/>",
"    Thur &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;305 (16.9) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;No exercise",
"    <br/>",
"    Fri &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 280 (15.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Exercised on treadmill",
"    <br/>",
"    Sat &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;190 (10.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;3-mile walk. No donuts!",
"    <br/>",
"    Sun &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;174 (9.7)",
"   </p>",
"   <p>",
"    Interpretation and approach &mdash; Daily fasting blood glucose values provide this woman with immediate feedback about the consequences of her behaviors. She can see that when she strays from her diet, her blood glucose values are higher the next morning, and when she exercises they are lower.",
"   </p>",
"   <p>",
"    After three weeks, she increases her exercise program to 45 minutes five evenings per week, and she rarely eats snacks in the evening. Her weight falls to 238 lbs (108 kg), her mean fasting blood glucose concentration is 178",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (9.9",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and her A1C value is 9.1 percent. She has learned a lot about diabetes and its possible future consequences from her reading and support group meetings, and has made her goal an A1C value below 8.0 percent (although a HbA1c of well below 7.0 percent would be a much better long-term goal). She is congratulated on the good lifestyle choices she has made and is encouraged to continue with these, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is now added, the dose being gradually increased to 2 grams daily in divided doses. She is asked to continue to measure her blood glucose every morning before breakfast and occasionally at other times.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the next month, her blood glucose values (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    during a typical week are as follows:",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Comments",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;breakfast &nbsp; &nbsp;lunch &nbsp; &nbsp; &nbsp; &nbsp; evening &nbsp; &nbsp; bedtime",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; meal",
"   </p>",
"   <p>",
"    Mon &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 156 (8.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 167 (9.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Evening exercise",
"    <br/>",
"    Tue &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;141 (7.8)",
"    <br/>",
"    Wed &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 178 (9.9) &nbsp; &nbsp;184 (10.2)",
"    <br/>",
"    Thur &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;160 (8.9) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Evening exercise",
"    <br/>",
"    Fri &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;157 (8.7) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Evening exercise",
"    <br/>",
"    Sat &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;159 (8.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Ate late, no exercise",
"    <br/>",
"    Sun &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 204 (11.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 172 (9.6)",
"   </p>",
"   <p>",
"    Interpretation and approach &mdash; Her mean fasting blood glucose concentration is now 165",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (9.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and the concentrations are higher later in the day. Her A1C value is 8.6 percent.",
"   </p>",
"   <p>",
"    She is congratulated on her progress, and is given several options. She could add a sulfonylurea, add a dose of NPH insulin at bedtime, or add a GLP-1 agonist like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14375?source=see_link\">",
"     exenatide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/47/21238?source=see_link\">",
"     liraglutide",
"    </a>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef70606 \" href=\"UTD.htm?7/63/8176\">",
"     algorithm 1",
"    </a>",
"    ). She elects to continue with lifestyle measures and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    but to add bedtime insulin. She is encouraged to reset her goal for HbA1c to below 7.0 percent. She is taught to take 12 units of NPH insulin at bedtime (10 pm) every evening, while continuing her other treatment. She is asked to measure fasting blood glucose every day and to report the values to you every week.",
"   </p>",
"   <p>",
"    During the next few weeks her bedtime dose of insulin is increased as follows:",
"   </p>",
"   <p>",
"    Week &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Mean fasting &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Bedtime dose of NPH",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;blood glucose",
"   </p>",
"   <p>",
"    1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;168 (9.3) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 12",
"    <br/>",
"    2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;165 (9.2) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 16",
"    <br/>",
"    3 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;154 (8.6) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 20",
"    <br/>",
"    4 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;148 (8.2) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 24",
"    <br/>",
"    5 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;140 (7.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 28",
"    <br/>",
"    6 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;133 (7.4) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 32",
"    <br/>",
"    7 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;134 (7.4) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 32",
"   </p>",
"   <p>",
"    Interpretation and approach &mdash; By measuring fasting blood glucose daily and averaging the values each week the dose of bedtime NPH insulin can be adjusted to an appropriate level.",
"   </p>",
"   <p>",
"    Over the next year her A1C values are between 6.5 and 7.5 percent. She is asked to continue measuring fasting blood glucose every day and occasionally at other times. During the following year her A1C value rises to 8.4 percent, despite fasting blood glucose concentrations &lt;130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    She is asked to measure blood glucose more often before lunch and dinner and at bedtime.",
"   </p>",
"   <p>",
"    During the next three months, her blood glucose concentrations (in",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    and, in parentheses,",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    during a typical week are:",
"   </p>",
"   <p>",
"    Day &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Before &nbsp; &nbsp; &nbsp; &nbsp; Before &nbsp; &nbsp; &nbsp; &nbsp; Before",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; breakfast &nbsp; &nbsp; lunch &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; evening &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;bedtime",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;meal",
"   </p>",
"   <p>",
"    Mon &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;119 (6.6) &nbsp; &nbsp; &nbsp;198 (11.0) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 235 (13.1)",
"    <br/>",
"    Tue &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;128 (7.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;251 (13.9)",
"    <br/>",
"    Wed &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 147 (8.2) &nbsp; &nbsp; &nbsp; 236 (13.1) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;266 (14.8)",
"    <br/>",
"    Thur &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;123 (6.8) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;241 (13.4)",
"    <br/>",
"    Fri &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 130 (7.2)",
"   </p>",
"   <p>",
"    Interpretation and approach &mdash; Although her fasting blood glucose concentrations remain within the target range, they are rising steadily throughout the day. This is probably due to progression of type 2 diabetes, so that her pancreatic beta-cells are making less insulin than they used to. She is advised to continue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and NPH insulin at bedtime. Because the target A1C has not been achieved, the insulin regimen should be intensified. She could add a second dose of NPH insulin before breakfast and take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    before her evening meal. She starts to measure blood glucose before breakfast, lunch, and dinner and at bedtime, and starts to use an algorithm to select premeal doses of insulin (",
"    <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"UTD.htm?19/63/20467\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A complete discussion of the management of hyperglycemia can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overall comments",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this case (based on an actual clinical case) we are trying to show how testing blood glucose at different times of the day and in different situations can help in making treatment decisions. There are several aspects of this case that are currently managed somewhat differently than in the past. While everyone would advocate vigorous support of healthy lifestyle change for a woman like this, many clinicians would recommend adding drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insulin at an earlier stage in an effort to get her HbA1c well below 7.0 percent as quickly as possible. One of the most common reasons for patients having an HbA1c that is too high is \"clinical inertia\" where additional treatments in a stepped protocol are not added soon enough.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1778 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11332=[""].join("\n");
var outline_f11_4_11332=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overall comments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1778\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1778|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/63/8176\" title=\"algorithm 1\">",
"      Management type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?19/63/20467\" title=\"algorithm 2\">",
"      Insulin titration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_4_11333="Pharmacology of bisphosphonates";
var content_f11_4_11333=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of bisphosphonates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11333/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11333/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11333/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11333/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11333/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11333/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/4/11333/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review provides an overview of the pharmacology of the bisphosphonates and of the differences between the preparations that are either currently available or undergoing clinical testing. Because bisphosphonates inhibit bone resorption, they are used in the treatment of hypercalcemia, osteoporosis, metastatic bone disease, and Paget disease. These uses are discussed separately.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates all have in common the P&ndash;C&ndash;P structure, which is similar to the P&ndash;O&ndash;P structure of native pyrophosphate (",
"    <a class=\"graphic graphic_figure graphicRef65606 \" href=\"UTD.htm?19/2/19500\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/1\">",
"     1",
"    </a>",
"    ]. Bisphosphonates differ from each other only at the two \"R\" groups in the accompanying figures (",
"    <a class=\"graphic graphic_figure graphicRef65606 \" href=\"UTD.htm?19/2/19500\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82089 \" href=\"UTD.htm?23/14/23789\">",
"     figure 2",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    , neridronate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    have a nitrogen group and are called nitrogen-containing bisphosphonates in contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    , which do not&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef82089 \" href=\"UTD.htm?23/14/23789\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bisphosphonates inhibit osteoclastic bone resorption via a mechanism that differs from that of other antiresorptive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Bisphosphonates attach to hydroxyapatite binding sites on bony surfaces, especially surfaces undergoing active resorption. When osteoclasts begin to resorb bone that is impregnated with bisphosphonate, the bisphosphonate released during resorption impairs the ability of the osteoclasts to form the ruffled border, to adhere to the bony surface, and to produce the protons necessary for continued bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ]. Bisphosphonates also reduce osteoclast activity by decreasing osteoclast progenitor development and recruitment and by promoting osteoclast apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to their inhibitory effect on osteoclasts, bisphosphonates appear to have a beneficial effect on osteoblasts. In a murine model of glucocorticoid-induced osteoporosis, bisphosphonates prevented osteocyte and osteoblast apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/7\">",
"     7",
"    </a>",
"    ]. The mechanism of this effect involves connexin 43, a gap junction protein that facilitates activation of protein kinases. This anti-apoptotic effect, however, probably does not contribute significantly to the anti-osteoporotic efficacy of bisphosphonates, above their potent antiresorptive actions.",
"   </p>",
"   <p>",
"    Bone formation is often reduced by bisphosphonates, which is probably an indirect effect of inhibition of bone resorption. In normal bone remodeling, bone resorption and formation are coupled. Changes in resorption drive formation, so, when bone resorption decreases, bone formation also decreases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link&amp;anchor=H1206113#H1206113\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\", section on 'Remodeling'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite their structural similarities, there are important differences among the bisphosphonates in potency and toxicity. The nitrogen-containing bisphosphonates (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , neridronate, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ) are more potent inhibitors of bone resorption than the simple bisphosphonates (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef50479 \" href=\"UTD.htm?6/1/6171\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Nitrogen-containing bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nitrogen-containing bisphosphonates act primarily by inhibiting the enzyme farnesyl pyrophosphate (FPP) synthase in the mevalonate pathway (cholesterol biosynthetic pathway). Inhibition of FPP synthase disrupts protein prenylation, which creates cytoskeletal abnormalities in the osteoclast, promotes detachment of the osteoclast from the bone perimeter, and leads to reduced bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The relative antiresorptive potency of the individual nitrogen-containing bisphosphonates is related to the potency within which they inhibit FPP synthase [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a histomorphometric study of bone biopsy specimens from postmenopausal women treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    for two to three years, a dose-dependent increase in the number of normal-appearing and abnormal osteoclasts was reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/13\">",
"     13",
"    </a>",
"    ]. Approximately one-third of the osteoclasts were giant, multinucleated, and detached, a finding that theoretically could be attributed to a nitrogen-containing bisphosphonate-induced prolongation of apoptosis, secondary to decreased osteoclast exposure to the high calcium concentration (an important signal for osteoclast death) that would normally be released during active bone resorption. Similar multinucleated giant cells are present in bone biopsy specimens from patients with Paget disease of bone or hyperparathyroidism, which could lead to an incorrect diagnosis. However, in the latter two conditions, there is evidence of active bone formation (abundant osteoblasts and osteoid), whereas long-term nitrogen-containing bisphosphonate therapy is associated with a reduction in bone formation (decreased osteoblasts, osteoid). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When FPP synthase is disrupted, there is an accumulation of a precursor, isopentenyl pyrophosphate (IPP), which can bind to a receptor and cause the release of tumor necrosis factor (TNF) alpha. This pathway, leading to the production of TNF alpha, is hypothesized to cause the acute-phase reaction, a well-recognized side effect of intravenous bisphosphonates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H42#H42\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Flu-like symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Simple bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates that do not contain nitrogen have a different mode of action. They are metabolized by osteoclasts to metabolites that exchange with the terminal pyrophosphate moiety of ATP, resulting in an ATP that cannot be used as a source of energy. The osteoclasts then undergo apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mineralization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyrophosphate is an important inhibitor of mineralization, and it is prevented from entering the bone by alkaline phosphate in the bone lining cells. The bisphosphonates, which have a structure similar to native pyrophosphate, have a strong affinity to mineral and they are not cleaved by the alkaline phosphatase. Thus, they can inhibit mineralization.",
"    <br/>",
"   </p>",
"   <p>",
"    However, there are differences among the bisphosphonates in their potential to inhibit mineralization and cause osteomalacia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     Etidronate",
"    </a>",
"    , as an example, inhibits bone resorption and mineralization at the same concentration. This unfavorable therapeutic index (1:1) is the reason why etidronate is used infrequently for the treatment of osteoporosis. In comparison, the dose of nitrogen-containing bisphosphonates that inhibits bone mineralization is 1000 times the dose that inhibits bone resorption. One study of transiliac bone biopsies 24 or 36 months after the start of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    treatment confirmed that bone mineralization was normal and trabecular bone resorption was markedly decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, the circulating concentrations of the nitrogen-containing bisphosphonates currently in use inhibit skeletal resorption but do not cause osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are poorly absorbed orally (1 to 5 percent of an oral dose), and absorption is best when they are given on an empty stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/16\">",
"     16",
"    </a>",
"    ]. We recommend that oral bisphosphonates be taken only with water and that the patient then wait at least 30 minutes before ingesting food or other medications. More convenient oral dosing regimens, eg, once weekly or monthly, are available and are preferred by most patients. Intravenous preparations, which require even less frequent dosing, are also available for those unable to tolerate oral regimens.",
"   </p>",
"   <p>",
"    Approximately 70 percent of the absorbed bisphosphonate is cleared by the kidney, and the remaining 30 percent is taken up by bone. Relative bone uptake is increased in conditions of high bone turnover, with less of the drug being excreted by the kidneys. Bisphosphonates are cleared rapidly from the plasma (half-life is approximately one hour), but may persist in bone for the patient&rsquo;s lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11333/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL USE AND ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates can be given to patients with any condition characterized by excessive bone resorption, such as osteoporosis, hypercalcemia of any cause, metastatic bone disease, and Paget disease. They are also used to treat heritable skeletal disorders in children, such as osteogenesis imperfecta. The clinical efficacy and adverse effects of bisphosphonates are discussed in greater detail separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H2#H2\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'General principles'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"       \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of hypercalcemia\", section on 'Bisphosphonates'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link\">",
"       \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/35/33336?source=see_link\">",
"       \"Overview of the use of osteoclast inhibitors in early breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"       \"The use of bisphosphonates in patients with multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10602?source=see_link\">",
"       \"Treatment of Paget disease of bone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"       \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26185?source=see_link\">",
"       \"Osteogenesis imperfecta: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8538676\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bisphosphonates potently inhibit bone resorption by reducing osteoclast number and function. The nitrogen-containing bisphosphonates are more potent than the simple bisphosphonates. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The nitrogen-containing bisphosphonates work primarily by inhibiting the enzyme farnesyl pyrophosphate (FFP) synthase in the mevalonate pathway (cholesterol biosynthetic pathway), thereby disrupting protein prenylation, which creates cytoskeletal abnormalities in the osteoclast, promotes detachment of the osteoclast from the bone perimeter, and leads to reduced bone resorption. Antiresorptive potency is directly related to potency for inhibition of FFP synthase. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nitrogen-containing bisphosphonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Simple bisphosphonates have a different mechanism of action. They are metabolized by osteoclasts to metabolites that exchange with the terminal pyrophosphate moiety of ATP, resulting in an ATP that cannot be used as a source of energy. The osteoclasts then undergo apoptosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Simple bisphosphonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bisphosphonates are poorly absorbed orally (1 to 5 percent of an oral dose), but absorption is best when they are given on an empty stomach. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bisphosphonates may be clinically useful in any condition characterized by excessive bone resorption. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical use and adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/1\">",
"      Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/2\">",
"      Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97:2692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/3\">",
"      Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/4\">",
"      Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/5\">",
"      Colucci S, Minielli V, Zambonin G, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998; 63:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/6\">",
"      Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/7\">",
"      Plotkin LI, Lezcano V, Thostenson J, et al. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 2008; 23:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/8\">",
"      van beek E, L&ouml;wik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999; 14:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/9\">",
"      Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004; 75:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/10\">",
"      Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007; 119 Suppl 2:S150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/11\">",
"      Dunford JE. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition. Curr Pharm Des 2010; 16:2961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/12\">",
"      Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/13\">",
"      Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009; 360:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/14\">",
"      Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11333/abstract/15\">",
"      Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100:1475.",
"     </a>",
"    </li>",
"    <li>",
"     Fleisch H. Pharmacokinetics. In: Bisphosphonates in Bone Disease: From the Laboratory to the Patient, University of Berne, Berne, Switzerland 1993. p.50.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2024 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-113.53.254.124-B894B13FA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11333=[""].join("\n");
var outline_f11_4_11333=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8538676\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Nitrogen-containing bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Simple bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mineralization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL USE AND ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8538676\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2024|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/2/19500\" title=\"figure 1\">",
"      Bisphosphonate vs pyrophosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/14/23789\" title=\"figure 2\">",
"      Structure of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2024|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/1/6171\" title=\"table 1\">",
"      Bisphosphonates in order of potency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26185?source=related_link\">",
"      Osteogenesis imperfecta: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/35/33336?source=related_link\">",
"      Overview of the use of osteoclast inhibitors in early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10602?source=related_link\">",
"      Treatment of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16041?source=related_link\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_4_11334="Horizontal forehead rhytides at rest and contraction";
var content_f11_4_11334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Horizontal forehead rhytides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Horizontal wrinkles are present on the forehead. This patient has wrinkles that are visible at rest (top). The wrinkles are exacerbated during brow elevation (bottom).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11334=[""].join("\n");
var outline_f11_4_11334=null;
var title_f11_4_11335="Mendelian randomization";
var content_f11_4_11335=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mendelian randomization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11335/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11335/contributors\">",
"     George Thanassoulis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11335/contributors\">",
"     Christopher J O'Donnell, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11335/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11335/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11335/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11335/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/4/11335/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6156907\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mendelian randomization represents a novel epidemiologic study design that incorporates genetic information into traditional epidemiologic methods. Studies based on Mendelian randomization will likely become increasingly common as genetic knowledge of health and disease expands with data from genomewide association studies and genome sequencing. Mendelian randomization provides an approach to addressing questions of causality without many of the typical biases that impact the validity of traditional epidemiologic approaches.",
"   </p>",
"   <p>",
"    While Mendelian randomization studies can provide important suggestive evidence for causal relations between risk factor and disease outcome, they are not true experiments and are dependent on several assumptions. Evidence from randomized controlled trials, when possible, should continue to guide clinical decisions.",
"   </p>",
"   <p>",
"    This topic will discuss the rationale and limitations of Mendelian randomization as a study design. The principles of Mendelian inheritance, which are the basis for randomization of this study design, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"     \"Overview of Mendelian inheritance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156913\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Mendelian randomization design was first proposed in 1986 to evaluate whether low levels of LDL cholesterol increase cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/1\">",
"     1",
"    </a>",
"    ]. Observational studies had reported a higher risk of cancer in individuals with low LDL levels, compared with subjects with normal or elevated LDL levels. However, biases implicit in observational studies could not be excluded as an explanation for the observed association.",
"   </p>",
"   <p>",
"    Investigators proposed a natural experiment, suggesting that the effect of low LDL levels on cancer risk could be determined by comparing cancer rates in individuals with and without genotypes that predispose to low LDL level. The inheritance of a particular genotype, based on Mendel&rsquo;s second law of independent assortment, was far less likely to be influenced by lifestyle or environmental issues than LDL levels themselves. This hypothetical study, finally performed more than 20 years later when genetic data became more readily available, found no increased risk among individuals with lifelong low LDL levels [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Mendelian randomization limits several potential biases that are often seen in observational studies using traditional epidemiologic study designs. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confounding &mdash; Confounding occurs when factors (known or unknown) are associated with both the exposure of interest (ie, low LDL levels) and the outcome (ie, cancer) (",
"      <a class=\"graphic graphic_figure graphicRef67729 \" href=\"UTD.htm?1/31/1520\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/3\">",
"       3",
"      </a>",
"      ]. For example, an unknown carcinogen X that leads to both low LDL levels and cancer would be a potential confounder in the association between low LDL levels and cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8500?source=see_link&amp;anchor=H6#H6\">",
"       \"Proof, p-values, and hypothesis testing\", section on 'Explanation for the results of a study'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Confounding leads to mixing of the effect of the exposure of interest and of the confounding factor on the outcome of interest. Confounding-related bias can be excluded by randomization, or minimized by adjustment for confounding variables in multivariable models. Randomization, if successful, excludes all possible confounders (including unknown or unmeasured confounders). However, randomized trials are difficult, and often not feasible or ethical, to conduct. Multivariable models can adjust only for confounders that are known and measured in the study population.",
"     </li>",
"     <li>",
"      Reverse causality &mdash; Reverse causality occurs when the outcome affects the level of the exposure of interest, rather than the expected (reverse) direction of effect (",
"      <a class=\"graphic graphic_figure graphicRef79062 \" href=\"UTD.htm?28/4/28750\">",
"       figure 2",
"      </a>",
"      ). Reverse causality could represent an important bias in studies when the exposure variable is measured close to the time of outcome. For example, cancer may reduce LDL levels (due to cachexia), which could explain the association between low LDL levels and cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Mendelian randomization approach limits both confounding and reverse causality, allowing for improved causal inferences, under specific conditions described below. (See",
"    <a class=\"local\" href=\"#H6156931\">",
"     'Assumptions and limitations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156919\">",
"    <span class=\"h1\">",
"     STRUCTURE OF A MENDELIAN RANDOMIZATION STUDY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Mendelian randomization study is a prospective cohort study in which the exposure is defined based on the presence or absence of a specific allele (&ldquo;risk allele&rdquo;) that influences the risk factor of interest [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/4\">",
"     4",
"    </a>",
"    ]. Unlike most cohort studies, in which a single exposure-outcome association is estimated, three separate associations are ascertained in a Mendelian randomization study (",
"    <a class=\"graphic graphic_figure graphicRef56465 \" href=\"UTD.htm?32/59/33713\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Association 1: Between the risk allele (the instrumental variable) and the risk factor (the intermediate variable)",
"     </li>",
"     <li>",
"      Association 2: Between the risk allele and the outcome of interest",
"     </li>",
"     <li>",
"      Association 3: Between the intermediate variable (risk factor) and the outcome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Robust evidence for the first two associations is required for a Mendelian randomization study. Both qualitative and quantitative Mendelian randomization designs are possible; in most cases, a quantitative assessment is performed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/5\">",
"     5",
"    </a>",
"    ]. By using the estimates of association 1 and association 2, the investigator can determine the causal effect of the intermediate risk factor on the outcome. Association 3 represents the association which would normally be estimated in a traditional cohort study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156925\">",
"    <span class=\"h1\">",
"     CONCEPTUAL SIMILARITIES TO THE RANDOMIZED TRIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized clinical trials (RCTs) provide the highest level of evidence for the causal effect of an intervention on the occurrence of the outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. However, randomized trials are not always feasible (ie, there may be no intervention available) and may be unethical in certain situations (ie, randomization to an intervention which may cause harm). Furthermore, the generalizability of findings from some RCTs may be questioned, particularly when the study population is not representative of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative study designs, such as Mendelian randomization, have attempted to provide evidence of similar rigor to the RCT but in large population-based cohorts that are often more representative of the general population. The Mendelian randomization study design uses observational data and, unlike a randomized trial, is not a true experiment. However, there are several parallels with randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an RCT, an individual is randomized to an intervention and outcomes are ascertained. Similarly, in Mendelian randomization, individuals are randomized (at conception) to a genetic variant and outcomes are ascertained. In both the RCT and Mendelian randomization, the biological inference is that the difference in outcomes between the groups is due to a change in an intermediate factor. In the RCT, the effect on the intermediate factor is assumed (ie, statins improve outcomes by lowering LDL). However, in Mendelian randomization, the effect of the variant on the intermediate is confirmed and related back to the outcomes, providing a causal relation between the intermediate and the outcome. &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In an RCT, randomization is achieved by allocating the intervention in a random manner. This step prevents confounding and classifies the RCT as a true experiment. In a Mendelian randomization study, the randomization process occurs during gamete formation prior to conception. In this way, Mendelian randomization studies can be viewed as a natural experiment where individuals are randomly allocated to a certain allele at a given locus, as described by Mendel's second law of independent assortment of alleles. Mendel's second law states that the inheritance of alleles at different genetic loci are independent events, akin to flipping a coin. Therefore, the allocation of a given allele is random in the study population and not influenced by confounding demographic factors. However, there are at least two possible confounders, &ldquo;linkage disequilibrium&rdquo; and &ldquo;population stratification&rdquo;, that must be considered in such studies. (See",
"      <a class=\"local\" href=\"#H6156931\">",
"       'Assumptions and limitations'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"       \"Glossary of genetic terms\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In an RCT, the timing of the intervention (eg, allocation of drug) is known and the follow-up for events is prospective, which limits the possibility of reverse causality. Similarly, reverse causality is unlikely to bias the observations from Mendelian randomization studies as the future outcome cannot affect the allocation of a specific allele.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assuming that randomization is successful and losses to follow-up are minimized, inferences from an RCT are considered causal because they are true experiments. Thus, causal statements can be made based on RCT studies (ie, Drug A causes a reduction in events compared to placebo). Mendelian randomization studies are not as robust as RCTs with regard to ascribing causal effects, but represent the best available evidence for causal effects from observational data. (See",
"    <a class=\"local\" href=\"#H6156931\">",
"     'Assumptions and limitations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156931\">",
"    <span class=\"h1\">",
"     ASSUMPTIONS AND LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technically, a Mendelian randomization study is a type of &ldquo;instrumental variable&rdquo; study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/11\">",
"     11",
"    </a>",
"    ]. An instrumental variable is associated with variation in an intermediate factor but not with other factors that are known to influence the intermediate factor or the outcome (ie, not confounded by other factors) (",
"    <a class=\"graphic graphic_figure graphicRef56465 \" href=\"UTD.htm?32/59/33713\">",
"     figure 3",
"    </a>",
"    ). The genetic marker in Mendelian randomization acts as the instrumental variable. Due to the large number of false positive associations between candidate genetic markers and intermediate factors, Mendelian randomization requires careful selection of genetic markers; only replicated genetic markers with robust evidence for association with intermediate factors should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    An important misconception of Mendelian randomization studies is that such studies provide evidence to support the use of risk alleles in risk prediction for disease. Mendelian randomization studies use genetic information solely as an epidemiologic tool to evaluate the causal effects of modifiable risk factors; they provide no evidence for the clinical use of genetic markers associated with disease. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Assumptions that must be met in a Mendelian randomization to ensure validity of the study include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk allele is strongly associated with the intermediate factor and explains a significant proportion of the variation of the intermediate factor throughout the duration of the study (and preferably throughout life).",
"     </li>",
"     <li>",
"      The risk allele is not associated with other factors that can influence the intermediate factor.",
"     </li>",
"     <li>",
"      The risk allele acts on the outcome solely via its association with the intermediate factor. (See",
"      <a class=\"local\" href=\"#H6156961\">",
"       'Pleiotropy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these assumptions, several limitations to Mendelian randomization must be considered, including insufficient statistical power, confounding due to linkage disequilibrium or population stratification, pleiotropy, and canalization. In most Mendelian randomization studies, the current state of knowledge of genetics and biology makes it difficult to entirely exclude pleiotropy, linkage disequilibrium or canalization as possible biases in estimating causal effects. These potential biases therefore limit the evidence for (or against) causality from such studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156937\">",
"    <span class=\"h2\">",
"     Insufficient statistical power",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weak or inconsistent associations between the gene marker and the intermediate factor may lead to negative Mendelian randomization studies due to insufficient statistical power to detect an association. Mendelian randomization experiments need to be conducted in a population with sufficiently large sample size to reliably detect the association between the risk allele, the intermediate factor and the outcome of interest. Likewise, genetic loci that only explain a small fraction of the variation in the intermediate factor would produce insufficient differences in measures of the intermediate factor to have any detectable effect on the outcome. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156943\">",
"    <span class=\"h2\">",
"     Confounding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although Mendelian randomization avoids typical confounding, linkage disequilibrium and population stratification are two forms of confounding specific to genetic epidemiology studies (",
"    <a class=\"graphic graphic_figure graphicRef82064 \" href=\"UTD.htm?19/17/19733\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156949\">",
"    <span class=\"h3\">",
"     Linkage disequilibrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The independent assortment of alleles (Mendel's second law) does not apply uniformly to the entire genome. Therefore, the allocation of alleles at conception is not entirely random across all genetic loci. When two loci are in close proximity to each other on the same chromosome, the probability of allocation of these alleles from parents to offspring will be correlated. These loci are said to be &ldquo;in linkage disequilibrium&rdquo; (",
"    <a class=\"graphic graphic_figure graphicRef76528 \" href=\"UTD.htm?22/19/22845\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Confounding can arise when locus A, which is strongly associated with the intermediate factor, is in linkage disequilibrium (ie, in close physical proximity) with locus B, which is associated with the outcome. In this case, the risk allele at locus A will appear to be associated with both the intermediate factor and the outcome but the latter association occurs via locus B (and not through the intermediate factor). Therefore, the association between allele at locus A and disease would be confounded by locus B. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156955\">",
"    <span class=\"h3\">",
"     Population stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Population stratification represents confounding by ethnicity. For example, differences in allele frequencies and disease prevalence may exist among different ethnic groups unrelated to any true association between risk alleles and disease, leading to the faulty conclusion that risk alleles are associated with the disease outcome. In this case, the association between risk allele and disease would be confounded by ethnicity. Control for population stratification is possible using certain statistical techniques (eg, genomic control or principal component methods) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156961\">",
"    <span class=\"h2\">",
"     Pleiotropy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential limitation of Mendelian randomization is the existence of pleiotropy. Pleiotropy occurs when a genetic variant influences multiple phenotypic traits or has multiple biological effects. The core consideration for Mendelian randomization is that the association between the risk allele and the outcome is mediated via the intermediate factor. Therefore, alternative pathways from the risk allele to the disease outcome would severely compromise the concept of Mendelian randomization (",
"    <a class=\"graphic graphic_figure graphicRef62239 \" href=\"UTD.htm?2/26/2467\">",
"     figure 6",
"    </a>",
"    ). The risk allele locus selected for a Mendelian randomization study should have no other functions that could produce an association between the allele and the disease outcome (ie, no pleiotropy). As an example, if a risk allele is associated with lower cholesterol, but also lowers HDL (which may not be known), then if this allele were used in a Mendelian randomization study evaluating the effects of LDL on myocardial infarction risk, the effect of LDL lowering will be overestimated by the added effect of the HDL increase. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156967\">",
"    <span class=\"h2\">",
"     Canalization and gene-environment interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The validity of results from a Mendelian randomization study is limited when the effect of the risk allele on the intermediate factor or the outcome is modified via compensatory responses in utero or environmental influences during life. Canalization refers to the compensatory effects of mechanisms that act to buffer any genetic effect in utero or after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/16\">",
"     16",
"    </a>",
"    ]. For example, a risk allele associated with an increase in LDL in utero could lead to the upregulation of mechanisms (eg, via gene expression) to protect the individual from increased LDL. This would render the association between the risk allele and the disease outcome invalid for the purposes of estimating the effect of LDL in the general population.",
"   </p>",
"   <p>",
"    The absence of an association between a risk allele and an intermediate phenotype or a disease outcome also may result from the influence of multiple cumulative environmental effects during life, or from possible gene-environment interactions (eg, with age) that may nullify any genetic effects after a certain age. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156973\">",
"    <span class=\"h1\">",
"     MULTIPLE GENETIC MARKERS FOR MENDELIAN RANDOMIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mendelian randomization studies have generally been performed with single risk alleles, although gene scores that combine multiple risk alleles across several loci associated with the intermediate factor have also been performed. Gene scores may improve associations between the genetic marker and the intermediate risk factor, but they are more prone to confounding by LD and pleiotropic effects. However, the use of different instruments (ie, separate independent markers) strongly associated with the same risk factor that demonstrate consistent results can bolster the causal argument for the role of the risk factor by strengthening some of the assumptions (ie, by reducing the possibility that the association observed is due to pleiotropy or confounding by linkage disequilibrium since it would be very unlikely that independent markers in different regions of the genome would have similar pleiotropic effects or linkage disequilibrium patterns) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156979\">",
"    <span class=\"h1\">",
"     EXAMPLES OF MENDELIAN RANDOMIZATION IN THE LITERATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several important Mendelian randomization studies have been published. Two studies that provide insights into cardiovascular risk factors and are excellent examples of this study design are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156985\">",
"    <span class=\"h2\">",
"     Lipoprotein(a) and myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although numerous epidemiologic studies have demonstrated important associations between Lp(a) and cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/18-25\">",
"     18-25",
"    </a>",
"    ], it was unclear whether Lp(a) represented a risk marker or a causal factor for myocardial infarction. Using three large populations from Denmark, a Mendelian randomization study demonstrated that LPA gene variants influence Lp(a) plasma levels, and that LPA gene variants increase the risk of myocardial infarction (MI) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/26\">",
"     26",
"    </a>",
"    ]. Using an instrumental variable analysis, they show that a doubling in Lp(a) levels throughout life is associated with a 22 percent increase in the risk of MI. Because the allocation of the LPA alleles is randomized before conception, this provides an unconfounded estimate of the causal effect of Lp(a) levels on myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"     \"Lipoprotein(a) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This Mendelian randomization study met the major requirements for this study design:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LPA gene variants are strongly associated with Lp(a) plasma levels; such variants explain 30 to 60 percent of the variation of plasma Lp(a) levels and this remains consistent throughout life [",
"      <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/27\">",
"       27",
"      </a>",
"      ]. Thus, LPA gene variants represent one of the best genetic markers for Mendelian randomization.",
"     </li>",
"     <li>",
"      Population stratification is unlikely to confound the relations between LPA gene variants, Lp(a) levels and myocardial infarction as the study was performed in a relatively ethnically homogeneous population.",
"     </li>",
"     <li>",
"      The LPA genetic variants used in this study are known to regulate expression of the LPA gene (ie, regulatory variants) and therefore are likely to only influence Lp(a) levels and not have other pleiotropic effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    True absence of pleiotropic effects can rarely be proven, however. In addition, linkage disequilibrium with other loci which may have effects on Lp(a) levels or myocardial infarction cannot be fully excluded. These examples of unverifiable assumptions in Mendelian randomization may limit confidence in ascribing causal relationships from such a study design (as compared to an RCT). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156991\">",
"    <span class=\"h2\">",
"     CRP gene variants and myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;C-reactive protein (CRP) has been demonstrated to be a robust marker of increased cardiovascular risk in numerous populations. However, whether CRP plays a causal role in atherogenesis and cardiovascular disease remains unknown as no agents that specifically lower CRP exist (without affecting other risk factors).",
"   </p>",
"   <p>",
"    Two studies evaluated the causal role of CRP using the Mendelian randomization approach evaluating the impact of a genetically elevated CRP level and cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Despite clinically important differences in CRP levels between individuals with and without CRP risk alleles, both of these large adequately powered studies observed no differences in cardiovascular event rates in individuals with or without these CRP risk alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11335/abstract/28\">",
"     28",
"    </a>",
"    ]. These studies provide important evidence that CRP is unlikely to be a causal factor in atherosclerosis and that proposed strategies to reduce cardiovascular disease risk by directly lowering levels of CRP are unlikely to be effective. However, although CRP may not be a causal factor in cardiovascular disease, this observation does not have an impact on the importance of the role of CRP as a risk marker in cardiovascular risk prediction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6156997\">",
"    <span class=\"h1\">",
"     EVALUATING A MENDELIAN RANDOMIZATION ARTICLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians interpreting evidence from a Mendelian randomization article in the literature can use the following checklist to grade the strength of such a study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the study design based on the standard prospective cohort study (ie, incident, rather than prevalent, events)?",
"     </li>",
"     <li>",
"      Has the risk factor being studied been associated with the disease outcome in several independent studies?",
"     </li>",
"     <li>",
"      Has the risk allele used been reproducibly associated with the intermediate factor in several independent studies?",
"     </li>",
"     <li>",
"      Does the risk allele explain a reasonable amount of the variation in the intermediate factor? Is this consistent throughout the study follow-up?",
"     </li>",
"     <li>",
"      Is the mechanism underlying the association between the risk allele and the intermediate factor known (eg, is the genetic variant a known regulatory variant for the expression of the intermediate factor)?",
"     </li>",
"     <li>",
"      Is the risk allele known to have no other effects other than to influence the levels of the intermediate factor?",
"     </li>",
"     <li>",
"      Was a single risk allele used (as opposed to a gene score, which increases the possibility of pleiotropy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      confounding by linkage disequilibrium)? If more than one risk allele is known, did the authors examine additional risk alleles (known to strongly associate with the risk factor of interest) to confirm their findings? &nbsp;",
"     </li>",
"     <li>",
"      Have the authors estimated the following three associations in their study population and found statistically significant results?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Genetic variant(s) with intermediate factor;",
"     </li>",
"     <li>",
"      Genetic variant(s) with disease outcome;",
"     </li>",
"     <li>",
"      Intermediate factor with disease outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Was an instrumental variable analysis used to provide estimates of causal effect?",
"     </li>",
"     <li>",
"      Was randomization successful? (Demographic and clinical characteristics should be randomly distributed between the risk alleles with minimal differences).",
"     </li>",
"     <li>",
"      Did the authors consider confounding by population stratification or linkage disequilibrium with other loci? &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For negative Mendelian randomization studies, a few additional factors to be considered are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Was there a large enough sample size (ie, was power calculated)? This becomes increasingly important for weaker associations.",
"     </li>",
"     <li>",
"      Did the authors consider canalization?",
"     </li>",
"     <li>",
"      Did the authors consider gene-environment interactions (eg, age interactions) as an explanation?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6157003\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mendelian randomization represents a novel epidemiologic study design that incorporates genetic information into traditional epidemiologic methods to investigate potential risk factors for specified outcomes. Mendelian randomization minimizes many of the major biases of traditional epidemiologic observational studies. (See",
"      <a class=\"local\" href=\"#H6156907\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mendelian randomization is a natural experiment in which the independent assortment of alleles at a given locus randomly sorts individuals who do or don&rsquo;t have a specified allele. A prospective cohort study is done to evaluate whether the outcome of interest is found more commonly in individuals with the risk allele than in those without the allele. Because the risk allele is closely associated with a risk factor (intermediate variable) of interest, then it can be shown that the presence of the risk factor is likely a causal factor for the outcome of interest. (See",
"      <a class=\"local\" href=\"#H6156913\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The validity of Mendelian randomization is dependent upon random gene assortment at a polymorphic locus and a strong, direct, and unique association between the risk allele and risk factor. Studies are weakened by linkage disequilibrium, population stratification, inconsistent associations between allele and intermediate variable resulting in insufficient statistical power, canalization, and",
"      <span class=\"nowrap\">",
"       gene/environment",
"      </span>",
"      interactions. (See",
"      <a class=\"local\" href=\"#H6156931\">",
"       'Assumptions and limitations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mendelian randomization relies on several assumptions, some unverifiable, which can invalidate inferences for a causal association between risk factor and disease. In reviewing a study employing Mendelian randomization design, questions regarding potential confounding factors need to be considered. (See",
"      <a class=\"local\" href=\"#H6156997\">",
"       'Evaluating a Mendelian randomization article'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/1\">",
"      Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986; 1:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/2\">",
"      Trompet S, Jukema JW, Katan MB, et al. Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol 2009; 170:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/3\">",
"      Greenland S, Morgenstern H. Confounding in health research. Annu Rev Public Health 2001; 22:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/4\">",
"      Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/5\">",
"      Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat Methods Med Res 2007; 16:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/6\">",
"      Kaul S, Diamond GA. Trial and error. How to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol 2010; 55:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/7\">",
"      Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000; 342:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/8\">",
"      Stone GW, Pocock SJ. Randomized trials, statistics, and clinical inference. J Am Coll Cardiol 2010; 55:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/9\">",
"      Liberopoulos G, Trikalinos NA, Ioannidis JP. The elderly were under-represented in osteoarthritis clinical trials. J Clin Epidemiol 2009; 62:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/10\">",
"      Thanassoulis G, O'Donnell CJ. Mendelian randomization: nature's randomized trial in the post-genome era. JAMA 2009; 301:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/11\">",
"      Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health 1998; 19:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/12\">",
"      Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007; 297:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/13\">",
"      Lawlor DA, Windmeijer F, Smith GD. Is Mendelian randomization 'lost in translation?': comments on 'Mendelian randomization equals instrumental variable analysis with genetic instruments' by Wehby et al. Stat Med 2008; 27:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/14\">",
"      Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999; 55:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/15\">",
"      Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/16\">",
"      Rutherford SL. From genotype to phenotype: buffering mechanisms and the storage of genetic information. Bioessays 2000; 22:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/17\">",
"      Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 2012; 21:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/18\">",
"      Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008; 168:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/19\">",
"      Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009; 203:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/20\">",
"      Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/21\">",
"      Holmer SR, Hengstenberg C, Kraft HG, et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 2003; 107:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/22\">",
"      Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999; 100:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/23\">",
"      Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002; 163:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/24\">",
"      Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/25\">",
"      Shiffman D, O'Meara ES, Bare LA, et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2008; 28:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/26\">",
"      Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/27\">",
"      Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/28\">",
"      Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11335/abstract/29\">",
"      Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13514 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11335=[""].join("\n");
var outline_f11_4_11335=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6157003\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6156907\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6156913\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6156919\">",
"      STRUCTURE OF A MENDELIAN RANDOMIZATION STUDY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6156925\">",
"      CONCEPTUAL SIMILARITIES TO THE RANDOMIZED TRIAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6156931\">",
"      ASSUMPTIONS AND LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6156937\">",
"      Insufficient statistical power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6156943\">",
"      Confounding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6156949\">",
"      - Linkage disequilibrium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6156955\">",
"      - Population stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6156961\">",
"      Pleiotropy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6156967\">",
"      Canalization and gene-environment interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6156973\">",
"      MULTIPLE GENETIC MARKERS FOR MENDELIAN RANDOMIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6156979\">",
"      EXAMPLES OF MENDELIAN RANDOMIZATION IN THE LITERATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6156985\">",
"      Lipoprotein(a) and myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6156991\">",
"      CRP gene variants and myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6156997\">",
"      EVALUATING A MENDELIAN RANDOMIZATION ARTICLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6157003\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/13514\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/13514|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/31/1520\" title=\"figure 1\">",
"      Confounding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/4/28750\" title=\"figure 2\">",
"      Reverse causality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/59/33713\" title=\"figure 3\">",
"      Structure of a Mendelian randomization study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/17/19733\" title=\"figure 4\">",
"      Confounding in Mendelian randomization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/19/22845\" title=\"figure 5\">",
"      Linkage disequilibrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2467\" title=\"figure 6\">",
"      Genetic pleiotropy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=related_link\">",
"      Overview of Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8500?source=related_link\">",
"      Proof, p-values, and hypothesis testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_4_11336="Evaluation of occult gastrointestinal bleeding";
var content_f11_4_11336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of occult gastrointestinal bleeding",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11336/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11336/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11336/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11336/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11336/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/4/11336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2007, the American Gastroenterological Association proposed the following nomenclature to standardize terms used to describe chronic gastrointestinal (GI) blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occult bleeding refers to the initial presentation of a positive fecal occult blood test (FOBT) result",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      iron-deficiency anemia (IDA) when there is no evidence of visible blood loss to the patient or physician.",
"     </li>",
"     <li>",
"      Obscure bleeding is defined as bleeding from the GI tract that persists or recurs without an obvious etiology after upper endoscopy, colonoscopy, and radiologic evaluation of the small bowel (such as by small bowel follow-through or enteroclysis). Obscure bleeding is subdivided into overt or occult, depending upon the presence or absence of clinically evident bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major cause of iron deficiency in developed countries is blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/2\">",
"     2",
"    </a>",
"    ]. In men the blood loss is most commonly from the GI tract; in women, menstrual blood loss must also be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of patients with occult GI bleeding will be reviewed here. The evaluation of patients with obscure GI bleeding, overt GI bleeding, and the evaluation of occult GI blood loss as it relates to screening for colorectal cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF OCCULT GI BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for occult gastrointestinal (GI) bleeding is broad. Some of the more common causes include colon cancer, esophagitis, peptic ulcers, gastritis, inflammatory bowel disease, vascular ectasias, portal hypertensive gastropathy, diverticula, celiac disease, and gastric antral vascular ectasias. However, less common causes such as gastroesophageal cancers, hemosuccus pancreaticus, hemobilia, aortoenteric fistulas, endometriosis, and infections also need to be considered. In addition, hemorrhoids can rarely lead to a positive fecal occult blood test [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/4\">",
"     4",
"    </a>",
"    ]. While overt bleeding from hemorrhoids can result in anemia, anemia in the setting of occult GI bleeding should not be attributed to hemorrhoids. Non-gastrointestinal sources of blood loss such as hemoptysis and epistaxis can also cause a positive fecal occult blood test (",
"    <a class=\"graphic graphic_table graphicRef71768 \" href=\"UTD.htm?38/23/39293\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58308 \" href=\"UTD.htm?12/8/12427\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The medical history and physical examination can help focus the differential diagnosis. As examples, colon cancer is more likely in patients older than 50 years, while angiodysplasias are more common in patients with renal failure. The presence of oral telangiectasias may signal the presence of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome), and mucocutaneous pigmentation may be due to Peutz-Jeghers syndrome where hamartomatous polyps may ulcerate and cause occult GI bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link\">",
"     \"Uncommon causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12664?source=see_link\">",
"     \"Major causes of upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TESTING FOR OCCULT BLOOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for occult blood is stool based. The best method (digital examination versus a patient-submitted stool sample) for obtaining stool for testing is controversial. Digital examination of the rectum can cause local trauma and some suggest that stool obtained during rectal examination should not be tested because of possible false positives. However, most studies have shown similar rates of detection of significant lesions regardless of how the stool samples were obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Regardless of how the sample was collected, a positive test requires further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Guaiac based fecal occult blood test",
"    </span>",
"    &nbsp;&mdash;&nbsp;This test identifies hemoglobin by the presence of a peroxidase reaction that turns guaiac-impregnated paper blue. Different reagents are available: Hemoccult, Hemoccult II, Hemoccult R, and Hemoccult Sensa. Hemoccult Sensa is more sensitive than Hemoccult II for colorectal cancer detection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], but is less specific [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H4#H4\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Guaiac-based fecal occult blood test (gFOBT)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A positive test is more likely with more blood in the GI tract. For the Hemoccult II test, fecal blood loss of 10 mL per day (10 mg per gram of stool) is required for the test to be positive 50 percent of the time, although the test can be positive with levels of less than 1 mg per gram of stool [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While dietary factors may influence the test results, studies have shown that a restrictive diet may not be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/14\">",
"     14",
"    </a>",
"    ]. False positive results can be seen with ingestion of red meat and dietary peroxidases (found in turnips and radishes). Vitamin C can lead to false negative results. By contrast, oral iron supplements do not result in a false positive result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A major problem with guaiac based fecal occult blood testing is the high rate of false positive results. In healthy populations, 1 to 16 percent will have positive occult blood tests and over 80 percent of these tests will be false positives [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In a systematic review, the positive predictive value for a fecal occult blood test predicting colon cancer ranged from 0.9 to 18.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, fecal occult blood testing has low sensitivity for colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunochemical tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests for occult blood include immunologic assays for intact human hemoglobin, which may detect as little as 0.3 mg per gram of stool (HemeSelect, FECA, I-FOBT, and Hemoccult ICT) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/18\">",
"     18",
"    </a>",
"    ]. These tests react only to human hemoglobin and do not detect upper GI bleeding, since hemoglobin is digested in the small bowel. These tests are more specific than guaiac tests, and appear to be equal to or more sensitive than Hemoccult II (guaiac based) when used for colorectal cancer screening [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/10,19-22\">",
"     10,19-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Current screening recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colorectal cancer screening is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link&amp;anchor=H9#H9\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Tests used for screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION OF A POSITIVE FECAL OCCULT BLOOD TEST",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992491\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following approach is consistent with the 2007 American Gastroenterological Association guidelines on obscure gastrointestinal (GI) bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of a patient with a positive fecal occult blood test depends upon whether iron deficiency anemia is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992944\">",
"    <span class=\"h3\">",
"     Without iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with a positive fecal occult blood test and no anemia should undergo a colonoscopy. If the patient also has upper gastrointestinal symptoms, an upper endoscopy should also be performed. Further testing in these patients is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992510\">",
"    <span class=\"h3\">",
"     With iron deficiency anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with a positive fecal occult blood test and iron deficiency anemia should undergo upper endoscopy and colonoscopy. Since there is often uncertainty as to whether a positive finding on one endoscopic examination represents the true cause of bleeding, both examinations are recommended in the majority of cases. However, the risks of diagnostic testing must be weighed against those of missing important lesions.",
"   </p>",
"   <p>",
"    Patients without a lesion identified on standard endoscopic evaluation (assuming the examination was adequate) should have a small bowel examination. We agree with the AGA guideline that, when available, the small bowel examination of choice in the majority of patients is wireless capsule endoscopy (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Small bowel evaluation'",
"    </a>",
"    below). If the initial evaluation with upper endoscopy, colonoscopy, and capsule endoscopy is unrevealing, alternative non-GI sources for the patient&rsquo;s iron deficiency should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    .) If the suspicion for a GI source of blood loss remains high, additional testing is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H992963\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Upper endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important lesions in the upper digestive tract are frequently detected in patients who test positive for fecal occult blood or have iron deficiency anemia (",
"    <a class=\"graphic graphic_picture graphicRef68358 \" href=\"UTD.htm?13/16/13583\">",
"     picture 1",
"    </a>",
"    ). While the presence of symptoms referable to the upper gastrointestinal tract has been associated with the detection of corresponding findings, even in patients without symptoms, the prevalence of lesions in the upper gastrointestinal tract is greater than or equal to that of colonic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/19,23-25\">",
"     19,23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12442?source=see_link\">",
"     \"Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of studies have evaluated the yield of performing upper endoscopy or small bowel examination in patients who have a positive test for occult blood, iron deficiency anemia, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/5,9,26-28\">",
"     5,9,26-28",
"    </a>",
"    ]. As examples, upper GI sources of bleeding were found in 36 to 56 percent of patients with iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/26-28\">",
"     26-28",
"    </a>",
"    ], and in 13 to 28 percent of patients with positive fecal occult blood tests without iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. The proportion of patients with both upper and lower GI lesions ranged from 5 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/9,27,28\">",
"     9,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high prevalence of colorectal cancer and adenomatous polyps in developed countries, most patients should undergo colonoscopy. Colonoscopy is the preferred modality because it can detect a wide range of lesions, including polyps, cancers, and angiodysplasias. Colonoscopy also permits therapeutic intervention.",
"   </p>",
"   <p>",
"    Radiographic studies (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enemas and CT colonography, also called \"virtual colonoscopy\") do not offer the option of biopsy or polypectomy. However, they may have a role in selected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36632?source=see_link\">",
"     \"Computed tomographic colonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Small bowel evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If complete endoscopy and colonoscopy with adequate visualization do not reveal the source of the bleed, additional evaluation is recommended. While an upper GI series with a small bowel follow-through",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enteroclysis was traditionally the next test performed, where available, CT enterography, magnetic resonance (MR) enterography and wireless capsule endoscopy have largely replaced these modalities.",
"   </p>",
"   <p>",
"    An upper GI with small bowel follow-through involves ingestion of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    solution with subsequent radiologic imaging of the small intestine. However, small bowel erosions, ulcerations, and angiodysplasias can be missed with this test.",
"   </p>",
"   <p>",
"    Enteroclysis is performed by passing a tube into the proximal small bowel and injecting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    , and air, followed by radiographic imaging. This is felt to be superior to standard small bowel follow-through testing, but the yield has been less than 20 percent in many studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. In addition, the test is extremely uncomfortable for patients and has been largely replaced by CT enterography.",
"   </p>",
"   <p>",
"    CT enterography involves ingestion of a neutral contrast agent to distend the small bowel, followed by CT imaging of the abdomen. Using neutral contrast allows for better evaluation of the wall of the small bowel, which is difficult to see when standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    solutions are used.",
"   </p>",
"   <p>",
"    MR enterography is an alternative to CT enterography. It has the advantage of not using ionizing radiation, which allows for sequential imaging of the small bowel. Like CT enterography, a neutral contrast agent (often polyethylene glycol) is used to distend the small bowel.",
"   </p>",
"   <p>",
"    With increasing availability of and experience with wireless capsule endoscopy (WCE), many gastroenterologists will omit radiographic imaging, opting instead to proceed directly with WCE for small bowel evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/33\">",
"     33",
"    </a>",
"    ]. Many insurance companies now cover WCE as a third line test for occult gastrointestinal bleeding, without requiring that patients undergo radiographic evaluation. Capsule endoscopy is equally or more sensitive than other methods for the diagnosis of small bowel sources of blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"     \"Wireless video capsule endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other methods available for evaluating the small bowel include push enteroscopy, deep small bowel enteroscopy, and intraoperative enteroscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53808641\">",
"    <span class=\"h1\">",
"     EVALUATION OF ISOLATED IRON DEFICIENCY ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unexplained iron deficiency anemia but a negative fecal occult blood test should be evaluated for a GI source of blood loss. This is particularly important in men and postmenopausal women. In patients with isolated iron deficiency anemia, a diagnosis of celiac disease should be considered and serologic evaluation with IgA and anti-tissue transglutaminase antibody should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .) If patients have symptoms suggesting either an upper or lower GI source, it is reasonable to start the evaluation with an upper endoscopy or colonoscopy, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/35\">",
"     35",
"    </a>",
"    ]. For patients who are asymptomatic, a colonoscopy is usually the first test obtained. In patients with profound anemia, it is reasonable to start the evaluation with both an upper endoscopy and a colonoscopy. (See",
"    <a class=\"local\" href=\"#H992963\">",
"     'Diagnostic tests'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who do not have a lesion identified during colonoscopy that explains the anemia should undergo an upper endoscopy, and vice versa. If both upper endoscopy and colonoscopy are negative additional testing, such as wireless capsule endoscopy should be pursued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"     \"Evaluation of obscure gastrointestinal bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SPECIAL SITUATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patients with a known risk factor for gastrointestinal blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive fecal occult blood test should not be attributed to gastrointestinal lesions that are infrequently associated with occult bleeding (eg, esophageal varices and colonic diverticula). It is rare for esophagogastric varices to cause occult GI bleeding, with the possible exception of those that have been treated with endoscopic sclerosis or banding. Similarly, most patients with bleeding colonic diverticular disease present with overt, rather than occult, bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=see_link\">",
"     \"Clinical manifestations and diagnosis of colonic diverticular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38679?source=see_link\">",
"     \"Colonic diverticular bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, in a patient with known esophagogastric varices or colonic diverticula, a positive test for occult blood or otherwise unexplained iron deficiency anemia should not preclude a diagnostic evaluation. Colonic diverticula commonly occur in the age bracket with the highest incidence of colon cancer, and colon cancer is far more likely to bleed in an occult manner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Aspirin, antiplatelet agents, and warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are conflicting regarding the effect of antiplatelet agents and anticoagulants on fecal occult blood testing [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/36-39\">",
"     36-39",
"    </a>",
"    ], and, if possible, these agents should be discontinued prior to fecal occult blood testing. However, it should",
"    <strong>",
"     not",
"    </strong>",
"    be assumed that a positive test in a patient on one of these agents is a false-positive.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , nonsteroidal antiinflammatory agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was associated with lower positive predictive values of fecal occult blood testing for advanced colorectal neoplasia compared with patients not taking these agents (21, 19, 7, and 20 percent, respectively, versus 31 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, the use of low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was associated with an increased sensitivity for detecting advanced colorectal neoplasms with only a slight decrease in specificity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53808810\">",
"    <span class=\"h2\">",
"     Alcohol abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of fecal occult blood should not be attributed to alcohol ingestion alone unless coexistent pathology has been excluded. In a study of 1000 patients hospitalized for alcohol detoxification, 22 patients (2.2 percent) without overt gastrointestinal bleeding tested positive for occult blood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/40\">",
"     40",
"    </a>",
"    ]. The subsequent endoscopic evaluation found that 24 percent of these individuals had peptic ulcer disease, 32 percent had premalignant colonic neoplasia, and all had upper GI mucosal inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to premenopausal women with iron deficiency anemia is uncertain. In one series, a clinically important lesion was detected in 23 of 186 premenopausal women (12 percent) who underwent endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/41\">",
"     41",
"    </a>",
"    ]. The most common source of bleeding was in the upper gastrointestinal tract, including peptic ulcer disease (3 percent) and gastric cancer (3 percent). On multivariable analysis, independent predictors of a significant finding on endoscopy included a positive fecal occult blood test, hemoglobin &lt;10",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and abdominal symptoms. Another study of 187 premenopausal women found an exclusive and possible gastrointestinal cause for iron deficiency anemia in 27 and 35 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11336/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the high prevalence of positive findings in these studies may have reflected referral bias, endoscopic evaluation should be obtained in premenopausal women who have a positive test for fecal occult blood, anemia out of proportion to menstrual blood loss, abdominal symptoms, or a family history of gastrointestinal malignancy, particularly in those older than 40 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       \"Patient information: Colonoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=see_link\">",
"       \"Patient information: Angiodysplasia of the GI tract (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occult bleeding refers to the initial presentation of a positive fecal occult blood test (FOBT)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      iron deficiency anemia when there is no evidence of visible blood loss to the patient or physician. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing for occult bleeding should be done with high sensitivity tests for fecal occult blood or immunochemical tests. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link&amp;anchor=H9#H9\">",
"       \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Tests used for screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a positive FOBT but without iron deficiency anemia should be evaluated by colonoscopy. If upper gastrointestinal (GI) tract symptoms are present, an upper endoscopy should also be performed. If these tests are negative, additional testing usually is not recommended. (See",
"      <a class=\"local\" href=\"#H992491\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H992963\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a positive FOBT and anemia should be evaluated with upper endoscopy and colonoscopy. If these studies are unrevealing, we recommend evaluation for a small bowel source of bleeding, preferably with wireless capsule endoscopy. (See",
"      <a class=\"local\" href=\"#H992491\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H992963\">",
"       'Diagnostic tests'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"       \"Wireless video capsule endoscopy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If wireless capsule endoscopy is not available, or if the patient has a contraindication to it, radiographic testing can be obtained. Radiographic tests to evaluate the small bowel include upper GI series with small bowel follow-through",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      enteroclysis and computed tomographic or magnetic resonance enterography. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Small bowel evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If the initial evaluation with upper endoscopy, colonoscopy, and capsule endoscopy is unrevealing, alternative non-GI sources for the patient&rsquo;s iron deficiency should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\"",
"      </a>",
"      .) If the suspicion for a GI source of blood loss remains high, additional testing is indicated. (See",
"      <a class=\"local\" href=\"#H992491\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=see_link\">",
"       \"Evaluation of obscure gastrointestinal bleeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with iron deficiency anemia but a negative FOBT should also undergo an upper endoscopy and colonoscopy. Possible exceptions are patients with a clear alternative explanation for their iron deficiency anemia (eg, celiac disease or significant hematuria) and asymptomatic, young, premenopausal women who have mild iron deficiency, and who do not have a family history of gastrointestinal malignancy. (See",
"      <a class=\"local\" href=\"#H53808641\">",
"       'Evaluation of isolated iron deficiency anemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Premenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/1\">",
"      Raju GS, Gerson L, Das A, et al. American Gastroenterological Association (AGA) Institute medical position statement on obscure gastrointestinal bleeding. Gastroenterology 2007; 133:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/2\">",
"      Cook JD, Skikne BS. Iron deficiency: definition and diagnosis. J Intern Med 1989; 226:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/3\">",
"      Rockey DC. Occult gastrointestinal bleeding. N Engl J Med 1999; 341:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/4\">",
"      van Turenhout ST, Oort FA, Terhaar sive Droste JS, et al. Hemorrhoids detected at colonoscopy: an infrequent cause of false-positive fecal immunochemical test results. Gastrointest Endosc 2012; 76:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/5\">",
"      Bini EJ, Rajapaksa RC, Valdes MT, Weinshel EH. Is upper gastrointestinal endoscopy indicated in asymptomatic patients with a positive fecal occult blood test and negative colonoscopy? Am J Med 1999; 106:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/6\">",
"      Brint SL, DiPalma JA, Herrera JL. Is a Hemoccult-positive rectal examination clinically significant? South Med J 1993; 86:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/7\">",
"      Eisner MS, Lewis JH. Diagnostic yield of a positive fecal occult blood test found on digital rectal examination. Does the finger count? Arch Intern Med 1991; 151:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/8\">",
"      Burke CA, Tadikonda L, Machicao V. Fecal occult blood testing for colorectal cancer screening: use the finger. Am J Gastroenterol 2001; 96:3175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/9\">",
"      Rockey DC, Koch J, Cello JP, et al. Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests. N Engl J Med 1998; 339:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/10\">",
"      Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/11\">",
"      Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/12\">",
"      Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/13\">",
"      Stroehlein JR, Fairbanks VF, McGill DB, Go VL. Hemoccult detection of fecal occult blood quantitated by radioassay. Am J Dig Dis 1976; 21:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/14\">",
"      Pignone M. Faecal occult-blood screening in Burgundy. Lancet 2004; 364:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/15\">",
"      Levin B, Hess K, Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med 1997; 157:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/16\">",
"      Van Dam J, Bond JH, Sivak MV Jr. Fecal occult blood screening for colorectal cancer. Arch Intern Med 1995; 155:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/17\">",
"      Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/18\">",
"      Saito H. Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res 1996; 87:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/19\">",
"      Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/20\">",
"      Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/21\">",
"      Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/22\">",
"      van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/23\">",
"      Chen YK, Gladden DR, Kestenbaum DJ, Collen MJ. Is there a role for upper gastrointestinal endoscopy in the evaluation of patients with occult blood-positive stool and negative colonoscopy? Am J Gastroenterol 1993; 88:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/24\">",
"      Geller AJ, Kolts BE, Achem SR, Wears R. The high frequency of upper gastrointestinal pathology in patients with fecal occult blood and colon polyps. Am J Gastroenterol 1993; 88:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/25\">",
"      Hsia PC, al-Kawas FH. Yield of upper endoscopy in the evaluation of asymptomatic patients with Hemoccult-positive stool after a negative colonoscopy. Am J Gastroenterol 1992; 87:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/26\">",
"      Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med 1993; 329:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/27\">",
"      Till SH, Grundman MJ. Prevalence of concomitant disease in patients with iron deficiency anaemia. BMJ 1997; 314:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/28\">",
"      Kepczyk T, Kadakia SC. Prospective evaluation of gastrointestinal tract in patients with iron-deficiency anemia. Dig Dis Sci 1995; 40:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/29\">",
"      Williams RC Jr. Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med 2003; 349:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/30\">",
"      Bhutani MS, Gupta SC, Markert RJ, et al. A prospective controlled evaluation of endoscopic detection of angiodysplasia and its association with aortic valve disease. Gastrointest Endosc 1995; 42:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/31\">",
"      Pate GE, Mulligan A. An epidemiological study of Heyde's syndrome: an association between aortic stenosis and gastrointestinal bleeding. J Heart Valve Dis 2004; 13:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/32\">",
"      Leighton JA, Goldstein J, Hirota W, et al. Obscure gastrointestinal bleeding. Gastrointest Endosc 2003; 58:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/33\">",
"      Eliakim AR. Video capsule endoscopy of the small bowel (PillCam SB). Curr Opin Gastroenterol 2006; 22:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/34\">",
"      de Leusse A, Vahedi K, Edery J, et al. Capsule endoscopy or push enteroscopy for first-line exploration of obscure gastrointestinal bleeding? Gastroenterology 2007; 132:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/35\">",
"      Rockey DC. Occult and obscure gastrointestinal bleeding: causes and clinical management. Nat Rev Gastroenterol Hepatol 2010; 7:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/36\">",
"      Sawhney MS, McDougall H, Nelson DB, Bond JH. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or non-steroidal anti-inflammatory drugs. Dig Dis Sci 2010; 55:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/37\">",
"      Greenberg PD, Cello JP, Rockey DC. Asymptomatic chronic gastrointestinal blood loss in patients taking aspirin or warfarin for cardiovascular disease. Am J Med 1996; 100:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/38\">",
"      Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 2010; 304:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/39\">",
"      Kershenbaum A, Lavi I, Rennert G, Almog R. Fecal occult blood test performance indicators in warfarin-treated patients. Dis Colon Rectum 2010; 53:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/40\">",
"      Zwas FR, Lyon DT. Occult GI bleeding in the alcoholic. Am J Gastroenterol 1996; 91:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/41\">",
"      Bini EJ, Micale PL, Weinshel EH. Evaluation of the gastrointestinal tract in premenopausal women with iron deficiency anemia. Am J Med 1998; 105:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11336/abstract/42\">",
"      Vannella L, Aloe Spiriti MA, Cozza G, et al. Benefit of concomitant gastrointestinal and gynaecological evaluation in premenopausal women with iron deficiency anaemia. Aliment Pharmacol Ther 2008; 28:422.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2544 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11336=[""].join("\n");
var outline_f11_4_11336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF OCCULT GI BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TESTING FOR OCCULT BLOOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Guaiac based fecal occult blood test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunochemical tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Current screening recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION OF A POSITIVE FECAL OCCULT BLOOD TEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H992491\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H992944\">",
"      - Without iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H992510\">",
"      - With iron deficiency anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H992963\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Upper endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Small bowel evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53808641\">",
"      EVALUATION OF ISOLATED IRON DEFICIENCY ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patients with a known risk factor for gastrointestinal blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Aspirin, antiplatelet agents, and warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53808810\">",
"      Alcohol abuse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2544\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2544|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/16/13583\" title=\"picture 1\">",
"      Multiple duodenal ulcers Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2544|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/23/39293\" title=\"table 1\">",
"      Etiology acute UGI bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/8/12427\" title=\"table 2\">",
"      Common causes LGI bleeding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34919?source=related_link\">",
"      Clinical manifestations and diagnosis of colonic diverticular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38679?source=related_link\">",
"      Colonic diverticular bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36632?source=related_link\">",
"      Computed tomographic colonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/39/31352?source=related_link\">",
"      Evaluation of obscure gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12664?source=related_link\">",
"      Major causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12442?source=related_link\">",
"      Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/54/41826?source=related_link\">",
"      Patient information: Angiodysplasia of the GI tract (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=related_link\">",
"      Uncommon causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_4_11337="Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information";
var content_f11_4_11337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/24/10630?source=see_link\">",
"    see \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/20/10568?source=see_link\">",
"    see \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8084976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;;",
"     </li>",
"     <li>",
"      Asthmanefrin&trade; [OTC];",
"     </li>",
"     <li>",
"      Auvi-Q&trade;;",
"     </li>",
"     <li>",
"      EpiPen 2-Pak&reg;;",
"     </li>",
"     <li>",
"      EpiPen Jr 2-Pak&reg;;",
"     </li>",
"     <li>",
"      S2&reg; [OTC];",
"     </li>",
"     <li>",
"      Twinject&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8084977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;;",
"     </li>",
"     <li>",
"      Epi E-Z Pen&reg;;",
"     </li>",
"     <li>",
"      EpiPen&reg;;",
"     </li>",
"     <li>",
"      EpiPen&reg; Jr;",
"     </li>",
"     <li>",
"      Twinject&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8085209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8085094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Asystole/pulseless arrest, pulseless VT/VF (ACLS, 2010):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V., I.O.:",
"     </i>",
"     1 mg every 3-5 minutes until return of spontaneous circulation; if this approach fails, higher doses of epinephrine (up to 0.2 mg/kg) have been used for treatment of specific problems (eg, beta-blocker or calcium channel blocker overdose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Endotracheal:",
"     </i>",
"     2-2.5 mg every 3-5 minutes until I.V./I.O access established or return of spontaneous circulation; dilute in 5-10 mL NS or sterile water.",
"     <b>",
"      Note:",
"     </b>",
"     Absorption may be greater with sterile water (Naganobu, 2000). May cause false-negative reading with exhaled CO",
"     <sub>",
"      2",
"     </sub>",
"     detectors; use second method to confirm tube placement if CO",
"     <sub>",
"      2",
"     </sub>",
"     is not detected (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Bradycardia (symptomatic; unresponsive to atropine or pacing):",
"     </b>",
"     <i>",
"      I.V. infusion:",
"     </i>",
"     2-10 mcg/minute",
"     <b>",
"      or",
"     </b>",
"     0.1-0.5 mcg/kg/minute (7-35 mcg/minute in a 70 kg patient); titrate to desired effect (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bronchodilator:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      SubQ:",
"     </i>",
"     0.3-0.5 mg (",
"     <b>",
"      1:1000",
"     </b>",
"     [1 mg/mL] solution) every 20 minutes for 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nebulization:",
"     </i>",
"     S2&reg; (racepinephrine, OTC labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hand-bulb nebulizer: Add 0.5 mL (~10 drops) to nebulizer; 1-3 inhalations up to every 3 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Jet nebulizer: Add 0.5 mL (~10 drops) to nebulizer and dilute with 3 mL of NS; administer over ~15 minutes every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalation:",
"     </i>",
"     Primatene&reg; Mist (OTC labeling): One inhalation, wait at least 1 minute; if not relieved, may use once more. Do not use again for at least 3 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypersensitivity reaction (eg, anaphylaxis):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     SubQ administration results in slower absorption and is less reliable. I.M. administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (ACLS guidelines, 2010; Kemp, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., SubQ:",
"     </i>",
"     0.2-0.5 mg (",
"     <b>",
"      1:1000",
"     </b>",
"     [1 mg/mL] solution) every 5-15 minutes in the absence of clinical improvement (ACLS 2010; Kemp, 2008; Lieberman, 2010). If clinician deems appropriate, the 5-minute interval between injections may be shortened to allow for more frequent administration (Lieberman, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     0.1 mg (",
"     <b>",
"      1:10,000",
"     </b>",
"     [0.1 mg/mL] solution) over 5 minutes; may infuse at 1-4 mcg/minute to prevent the need to repeat injections frequently",
"     <b>",
"      or",
"     </b>",
"     may initiate with an infusion at 5-15 mcg/minute (with crystalloid administration) (ACLS, 2010; Brown, 2004). In general, I.V. administration should only be done in patients who are profoundly hypotensive or are in cardiopulmonary arrest refractory to volume resuscitation and several epinephrine injections (Lieberman, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Self-administration following severe allergic reactions (eg, insect stings, food):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     The World Health Organization (WHO) and Anaphylaxis Canada recommend the availability of one dose for every 10-20 minutes of travel time to a medical emergency facility. More than 2 sequential doses should only be administered under direct medical supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Auvi-Q&trade;: I.M., SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EpiPen&reg;: I.M., SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes using an additional EpiPen&reg;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Twinject&reg;: I.M., SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes using the same device after partial disassembly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypotension/shock, severe and fluid resistant (unlabeled use):",
"     </b>",
"     <i>",
"      I.V. infusion:",
"     </i>",
"     Initial: 0.1-0.5 mcg/kg/minute (7-35 mcg/minute in a 70 kg patient); titrate to desired response (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mydriasis during intraocular surgery, induction and maintenance:",
"     </b>",
"     Intraocular: Must dilute 1:",
"     <b>",
"      1000",
"     </b>",
"     (1 mg/mL) solution to a concentration of 1:",
"     <b>",
"      100,000",
"     </b>",
"     to 1:",
"     <b>",
"      1,000,000",
"     </b>",
"     (10",
"     <b>",
"      mcg",
"     </b>",
"     /mL to 1",
"     <b>",
"      mcg",
"     </b>",
"     /mL) prior to intraocular use: May use as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye) with a bolus dose of 0.1 mL of a 1:",
"     <b>",
"      100,000",
"     </b>",
"     to 1:",
"     <b>",
"      400,000",
"     </b>",
"     (10",
"     <b>",
"      mcg",
"     </b>",
"     /mL to 2.5",
"     <b>",
"      mcg",
"     </b>",
"     /mL) dilution.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8085093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/20/10568?source=see_link\">",
"      see \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Asystole/pulseless arrest, pulseless VT/VF (after failed defibrillation attempts) (PALS, 2010):",
"     </b>",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V., I.O.:",
"     </i>",
"     0.01 mg/kg (0.1 mL/kg of",
"     <b>",
"      1:10,000",
"     </b>",
"     [0.1 mg/mL] solution) (maximum single dose: 1 mg) every 3-5 minutes until return of spontaneous circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Endotracheal:",
"     </i>",
"     0.1 mg/kg (0.1 mL/kg of",
"     <b>",
"      1:1000",
"     </b>",
"     [1 mg/mL] solution) (maximum single dose: 2.5 mg) every 3-5 minutes until I.V./I.O access established or return of spontaneous circulation. Flush with 5 mL of NS immediately after administration. May cause false-negative reading with exhaled CO",
"     <sub>",
"      2",
"     </sub>",
"     detectors; use second method to confirm tube placement if CO",
"     <sub>",
"      2",
"     </sub>",
"     is not detected (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Postresuscitation infusion to maintain cardiac output or stabilize:",
"     </i>",
"     I.V., I.O.: 0.1-1 mcg/kg/minute; doses &lt;0.3 mcg/kg/minute generally produce beta-adrenergic effects and higher doses (&gt;0.3 mcg/kg/minute) generally produce alpha-adrenergic vasoconstriction; titrate dosage to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Bradycardia (symptomatic; unresponsive to atropine or pacing):",
"     </b>",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V., I.O.:",
"     </i>",
"     0.01 mg/kg (0.1 mL/kg of",
"     <b>",
"      1:10,000",
"     </b>",
"     [0.1 mg/mL] solution) (maximum single dose: 1 mg) every 3-5 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Endotracheal:",
"     </i>",
"     0.1 mg/kg or (0.1 mL/kg of",
"     <b>",
"      1:1000",
"     </b>",
"     [1 mg/mL] solution) (maximum single dose: 2.5 mg) every 3-5 minutes as needed until I.V./I.O. access established. Flush with 5 mL of NS immediately after administration. May cause false-negative reading with exhaled CO",
"     <sub>",
"      2",
"     </sub>",
"     detectors; use second method to confirm tube placement if CO",
"     <sub>",
"      2",
"     </sub>",
"     is not detected (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion:",
"     </i>",
"     I.V., I.O.: 0.1-1 mcg/kg/minute; doses &lt;0.3 mcg/kg/minute generally produce beta-adrenergic effects and higher doses (&gt;0.3 mcg/kg/minute) generally produce alpha-adrenergic vasoconstriction; titrate dosage to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Bronchodilator:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      SubQ:",
"     </i>",
"     Infants and Children: 0.01 mg/kg (0.01 mL/kg of",
"     <b>",
"      1:1000",
"     </b>",
"     [1 mg/mL] solution) (maximum single dose: 0.5 mg) every 20 minutes for 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Nebulization:",
"     </i>",
"     S2&reg; (racepinephrine, OTC labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;4 years: Jet nebulizer: Croup: 0.05 mL/kg (maximum dose: 0.5 mL); dilute in 3 mL of NS. Administer over ~15 minutes; do not administer more frequently than every 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;4 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;margin-right:2em;text-align:justify;\">",
"     <i>",
"      Inhalation:",
"     </i>",
"     Children &ge;4 years: Primatene&reg; Mist: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypersensitivity reaction (eg, anaphylaxis):",
"     </b>",
"     Infants and Children:",
"     <b>",
"      Note:",
"     </b>",
"     SubQ administration results in slower absorption and is less reliable. I.M. administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (ACLS guidelines, 2010; Kemp, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M., SubQ:",
"     </i>",
"     0.01 mg/kg (0.01 mL/kg of",
"     <b>",
"      1:1000",
"     </b>",
"     [1 mg/mL] solution) (maximum single dose: 0.3 mg) every 5-15 minutes; larger I.M. or SubQ doses, use of I.V. route, or continuous infusion may be needed for severe anaphylactic reactions (Kemp, 2008; Lieberman, 2010). If clinician deems appropriate, the 5-minute interval between injections may be shortened to allow for more frequent administration (Lieberman, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Self-administration following severe allergic reactions (eg, insect stings, food):",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     World Health Organization (WHO) and Anaphylaxis Canada recommend the availability of 1 dose for every 10-20 minutes of travel time to a medical emergency facility. More than 2 sequential doses should only be administered under direct medical supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Auvi-Q&trade;: I.M., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 15-29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EpiPen&reg; Jr: I.M., SubQ: Children 15-29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes using an additional EpiPen&reg; Jr",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EpiPen&reg;: I.M., SubQ: Children &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes using an additional EpiPen&reg;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Twinject&reg;: I.M., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 15-29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes using the same device after partial disassembly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes using the same device after partial disassembly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternate auto-injector dose:",
"     </i>",
"     I.M. (Sicherer, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 10-25 kg: 0.15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;25 kg: 0.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypotension/shock, fluid-resistant (unlabeled use):",
"     </b>",
"     Continuous I.V. infusion: 0.1-1 mcg/kg/minute; doses up to 5 mcg/kg/minute may rarely be necessary (Hegenbarth, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mydriasis  during intraocular surgery, induction and maintenance:",
"     </b>",
"     Intraocular: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8085095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15822429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8085180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 0.1 mg/mL (10 mL) [1:10,000 solution]; 1 mg/mL (1 mL) [1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Auvi-Q&trade;: 0.15 mg/0.15 mL (0.76 mL) [contains sodium bisulfite; 1:1000 solution; delivers 0.15 mL per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Auvi-Q&trade;: 0.3 mg/0.3 mL (0.76 mL) [contains sodium bisulfite; 1:1000 solution; delivers 0.3 mL per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EpiPen 2-Pak&reg;: 0.3 mg/0.3 mL (2 mL) [contains sodium metabisulfite; 1:1000 solution; delivers 0.3 mg per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EpiPen Jr 2-Pak&reg;: 0.15 mg/0.3 mL (2 mL) [contains sodium metabisulfite; 1:2000 solution; delivers 0.15 mg per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twinject&reg;: 0.15 mg/0.15 mL (1.1 mL [DSC]) [contains chlorobutanol, sodium bisulfite; 1:1000 solution; delivers 0.15 mg per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twinject&reg;: 0.3 mg/0.3 mL (1.1 mL [DSC]) [contains chlorobutanol, sodium bisulfite; 1:1000 solution; delivers 0.3 mg per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 1 mg/mL (30 mL) [1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adrenalin&reg;: 1 mg/mL (30 mL) [contains chlorobutanol, sodium bisulfite; 1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adrenalin&reg;: 1 mg/mL (1 mL) [contains sodium bisulfite; 1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 1 mg/mL (1 mL) [1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for oral inhalation [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asthmanefrin&trade;: Racepinephrine 2.25% (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     S2&reg;: Racepinephrine 2.25% (0.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8085003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution for injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8085143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     When administering as a continuous infusion, central line administration is preferred. I.V. infusions require an infusion pump. Epinephrine solutions for injection can be administered I.M., I.O., endotracheally, I.V., or SubQ.",
"     <b>",
"      Note:",
"     </b>",
"     Auvi-Q&trade;, EpiPen&reg; and EpiPen&reg; Jr Auto-Injectors contain a single, fixed-dose of epinephrine and may only be administered I.M. (preferred) or SubQ. Twinject&reg; Auto-Injectors contain two doses; the first fixed-dose is available for auto-injection; the second dose is available for manual injection following partial disassembly of device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Subcutaneous: SubQ administration results in slower absorption and is less reliable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     I.M.: I.M. administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (ACLS guidelines, 2010; Kemp, 2008). I.M. administration into the buttocks should be avoided. Auvi-Q&trade;, EpiPen&reg;, EpiPen&reg; Jr, and Twinject&reg; Auto-Injectors should only be injected into the anterolateral aspect of the thigh, through clothing if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Obesity:",
"     </i>",
"     In overweight or obese children, because skin surface to muscle depth is greater in the upper half of the thigh, administration into the lower half of the thigh may be preferred. In very obese children, injection into the calf will provide an even greater chance of intramuscular administration (Arkwright, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endotracheal (cardiac arrest): Dilute in NS or sterile water. Absorption may be greater with sterile water (Naganobu, 2000). Stop compressions, spray drug quickly down tube. Follow immediately with several quick insufflations and continue chest compressions. May cause false-negative reading with exhaled CO",
"     <sub>",
"      2",
"     </sub>",
"     detectors; use second method to confirm tube placement if CO",
"     <sub>",
"      2",
"     </sub>",
"     is not detected (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Oral inhalation: S2&reg;: If using jet nebulizer: Administer diluted over ~15 minutes. If using hand-held rubber bulb nebulizer, dilution is not required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Extravasation management:",
"     </b>",
"     Use phentolamine as antidote. Mix 5 mg phentolamine with 9 mL of NS. Inject a small amount of this dilution into extravasated area. Blanching should reverse immediately. Monitor site. If blanching should recur, additional injections of phentolamine may be needed.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg in 250 mL (concentration: 4",
"     <b>",
"      mcg",
"     </b>",
"     /mL)",
"     <b>",
"      or",
"     </b>",
"     4 mg in 250 mL (concentration: 16",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     16",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 32",
"     <b>",
"      mcg",
"     </b>",
"     /mL, or 64",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8085063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      2.5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, LR, NS, Ringer's injection;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), amiodarone, anidulafungin, atracurium, bivalirudin, caffeine citrate, calcium chloride, calcium gluconate, caspofungin, ceftazidime, cisatracurium, clonidine, dexmedetomidine, diltiazem, dobutamine, dopamine, famotidine, fenoldopam, fentanyl, furosemide, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, inamrinone, labetalol, levofloxacin, lorazepam, midazolam, milrinone, morphine, nicardipine, nitroglycerin, nitroprusside, norepinephrine, pancuronium,  phytonadione, potassium chloride, propofol, ranitidine, remifentanil, terbutaline, tigecycline, tirofiban, vasopressin, vecuronium, vitamin B complex with C, warfarin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ampicillin, micafungin, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Drotrecogin alfa, nesiritide, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, doxapram, heparin, hyaluronidase, inamrinone, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, milrinone.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Lidocaine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8085004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bronchospasms, bronchial asthma, viral croup, anaphylactic reactions, cardiac arrest; added to local anesthetics to decrease systemic absorption of intraspinal and local anesthetics and increase duration of action; decrease superficial hemorrhage; induction and maintenance of mydriasis during intraocular surgery",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8085006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ACLS guidelines: Ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) unresponsive to initial defibrillatory shocks; pulseless electrical activity; asystole; hypotension/shock unresponsive to volume resuscitation; symptomatic bradycardia unresponsive to atropine or pacing; inotropic support",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8084974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       EPINEPHrine may be confused with ePHEDrine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epifrin&reg; may be confused with ephedrine, EpiPen&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Medication errors have occurred due to confusion with epinephrine products expressed as ratio strengths (eg, 1:1000 vs 1:10,000).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epinephrine 1:1000 = 1 mg/mL and is most commonly used I.M.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epinephrine 1:10,000 = 0.1 mg/mL and is used I.V.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Medication errors have occurred when topical epinephrine 1 mg/mL (1:1000) has been inadvertently injected. Vials of injectable and topical epinephrine look very similar. Epinephrine should always be appropriately labeled with the intended administration.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       EpiPen [U.S., Canada, and multiple international markets] may be confused with Epigen brand name for glycyrrhizinic acid [Argentina, Mexico, Russia] and Epopen brand name for epoetin alfa [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8085039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, cardiac arrhythmia, chest pain, flushing, hypertension, pallor, palpitation, sudden death, tachycardia (parenteral), vasoconstriction, ventricular ectopy, ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety (transient), apprehensiveness, cerebral hemorrhage, dizziness, headache, insomnia, lightheadedness, nervousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dry throat, loss of appetite, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Acute urinary retention in patients with bladder outflow obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Allergic lid reaction, burning, corneal endothelial damage (intraocular use), eye pain, ocular irritation, precipitation of or exacerbation of narrow-angle glaucoma, transient stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8085011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no absolute contraindications to the use of injectable epinephrine (including Auvi-Q&trade;, EpiPen&reg;, EpiPen&reg; Jr, and Twinject&reg;) in a life-threatening situation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Oral inhalation: Concurrent use or within 2 weeks of MAO inhibitors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injectable solution: There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8085012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular diseases (eg, coronary artery disease, hypertension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with Parkinson's disease; may cause temporary worsening of symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tricyclic antidepressants: Use with caution in patients taking tricyclic antidepressants; effects of epinephrine may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary retention: Use with caution in patients with prostate enlargement or urinary retention; may cause temporary worsening of symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Accidental injection: Accidental injection into digits, hands, or feet may result in local reactions including injection site pallor, coldness and hypoesthesia or injury resulting in bruising, bleeding, discoloration, erythema or skeletal injury. Patient should seek immediate medical attention if this occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Rapid I.V. administration may cause death from cerebrovascular hemorrhage or cardiac arrhythmias. However, rapid I.V. administration during pulseless arrest is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some products contain sulfites as preservatives. The presence of sulfites in some products should not deter administration during a serious allergic or other emergency situation even if the patient is sulfite-sensitive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intraocular use: Must dilute 1:",
"     <b>",
"      1000",
"     </b>",
"     (1 mg/mL) solution to a concentration of 1:",
"     <b>",
"      100,000",
"     </b>",
"     to 1:",
"     <b>",
"      1,000,000",
"     </b>",
"     (10",
"     <b>",
"      mcg",
"     </b>",
"     /mL to 1",
"     <b>",
"      mcg",
"     </b>",
"     /mL) prior to intraocular use. When used undiluted, has been associated with corneal endothelial damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self medication (OTC use): Oral inhalation: Prior to self-medication, patients should contact healthcare provider. The product should only be used in persons with a diagnosis of asthma. If symptoms are not relieved in 20 minutes or become worse do not continue to use the product - seek immediate medical assistance. The product should not be used more frequently or at higher doses than recommended unless directed by a healthcare provider. This product should not be used in patients who have required hospitalization for asthma or if a patient is taking prescription medication for asthma. Do not use if you have taken a MAO inhibitor (certain drugs used for depression, Parkinson's disease, or other conditions) within 2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8085042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: EPINEPHrine (Systemic, Oral Inhalation) may enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F8085046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid ephedra, yohimbe (may cause CNS stimulation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8085007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8085008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. Epinephrine crosses the placenta and may cause fetal anoxia. Use during pregnancy when the potential benefit to the mother outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8085010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16335156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if epinephrine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering epinephrine to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8085182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Device",
"     </b>",
"     (Auvi-Q Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15 mg/0.15 mL (2): $289.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg/0.3 mL (2): $289.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Device",
"     </b>",
"     (EpiPen 2-Pak Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg/0.3 mL (2): $288.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Device",
"     </b>",
"     (EpiPen Jr 2-Pak Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15 mg/0.3 mL (2): $288.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Asthmanefrin Refill Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.25% (1): $1.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Asthmanefrin Starter Kit Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.25% (1): $5.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (Micronefrin Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.25% (15 mL): $25.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nebulization",
"     </b>",
"     (S2 Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.25% (1): $1.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Adrenalin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (30 mL): $9.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (EPINEPHrine HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1 mg/mL (10 mL): $5.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (30 mL): $8.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8085149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulmonary function, heart rate, blood pressure, site of infusion for blanching, extravasation; cardiac monitor and blood pressure monitor required during continuous infusion. If using to treat hypotension, assess intravascular volume and support as needed.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8085064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates alpha-, beta",
"     <sub>",
"      1",
"     </sub>",
"     -, and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors resulting in relaxation of smooth muscle of the bronchial tree, cardiac stimulation (increasing myocardial oxygen consumption), and dilation of skeletal muscle vasculature; small doses can cause vasodilation via beta",
"     <sub>",
"      2",
"     </sub>",
"     -vascular receptors; large doses may produce constriction of skeletal and vascular smooth muscle",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8085066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Bronchodilation: SubQ: ~5-10 minutes; Inhalation: ~1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Taken up into the adrenergic neuron and metabolized by monoamine oxidase and catechol-o-methyltransferase; circulating drug hepatically metabolized",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as inactive metabolites, metanephrine, and sulfate and hydroxy derivatives of mandelic acid, small amounts as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, Vignon P, Renault A, et al, &ldquo;Norepinephrine Plus Dobutamine Versus Epinephrine Alone for Management of Septic Shock: A Randomized Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9588):676-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/17720019/pubmed\" id=\"17720019\" target=\"_blank\">",
"        17720019",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arkwright P, Wright N, Bewick D, &ldquo;Anatomical and Anthropometric Determinants of Intramuscular versus Subcutaneous Administration in Children With Epinephrine Auto-injectors,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2013, 131(2):AB199.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brierley J, Carcillo JA, Choong K, et al, &ldquo;Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2009, 37(2):666-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/19325359/pubmed\" id=\"19325359\" target=\"_blank\">",
"        19325359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown SG, Blackman KE, Stenlake V, et al, \"Insect Sting Anaphylaxis; Prospective Evaluation of Treatment With Intravenous Adrenaline and Volume Resuscitation,\"",
"      <i>",
"       Emerg Med J",
"      </i>",
"      , 2004, 21(2):149-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/14988337/pubmed\" id=\"14988337\" target=\"_blank\">",
"        14988337",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cydulka R, Davison R, Grammer L, et al, &ldquo;The Use of Epinephrine in the Treatment of Older Adult Asthmatics,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1988, 17(4):322-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/3354935/pubmed\" id=\"3354935\" target=\"_blank\">",
"        3354935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis C and Wax P, &ldquo;Subcutaneous Epinephrine O.D. in a Child Resulting in Dysrhythmias and Myocardial Ischemia,&rdquo;",
"      <i>",
"       Vet Hum Toxicol",
"      </i>",
"      , 1994, 36:367.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goring-Morris J and Russell IF, &ldquo;A Randomized Comparison of 0.5% Bupivacaine With a Lidocaine/Epinephrine/Fentanyl Mixture for Epidural Top-up for Emergency Caesarean Section After &ldquo;Low Dose&rdquo; Epidural for Labour,&rdquo;",
"      <i>",
"       Int J Obstet Anesth",
"      </i>",
"      , 2006, 15(2):109-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/16488138/pubmed\" id=\"16488138\" target=\"_blank\">",
"        16488138",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gueugniaud PY, David JS, Chanzy E, et al, &ldquo;Vasopressin and Epinephrine vs. Epinephrine Alone in Cardiopulmonary Resuscitation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(1):21-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/18596271/pubmed\" id=\"18596271\" target=\"_blank\">",
"        18596271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollenberg SM, Ahrens TS, Annane D, et al, &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2004, 32(9):1928-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/15343024/pubmed\" id=\"15343024\" target=\"_blank\">",
"        15343024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Illi A, Sundberg S, Ojala-Karlsson P, et al, &ldquo;The Effect of Entacapone on the Disposition and Hemodynamic Effects of Intravenous Isoproterenol and Epinephrine,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 58(2):221-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/7648772/pubmed\" id=\"7648772\" target=\"_blank\">",
"        7648772",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011.  Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kartawiadi L, Vercauteren MP, Van Steenberge AL, et al, &ldquo;Spinal Analgesia During Labor With Low-dose Bupivacaine, Sufentanil, and Epinephrine. A Comparison with Epidural Analgesia,&rdquo;",
"      <i>",
"       Reg Anesth",
"      </i>",
"      , 1996, 21(3):191-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/8744659/pubmed\" id=\"8744659\" target=\"_blank\">",
"        8744659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kemp SF, Lockey RF, Simons FE, et al, &ldquo;Epinephrine: The Drug of Choice for Anaphylaxis. A Statement of the World Allergy Organization,&rdquo;",
"      <i>",
"       Allergy",
"      </i>",
"      , 2008, 63(8):1061-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/18691308/pubmed\" id=\"18691308\" target=\"_blank\">",
"        18691308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein JS, Rich MR, and Yunginger JW, &ldquo;Myocardial Ischemia Without Coronary Artery Disease After Epinephrine Overdose for Insect Sting Reaction,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1995, 95(2):371.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuracheck SC and Rockoff MA, &ldquo;Inadvertent Intravenous Administration of Racemic Epinephrine,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1984, 253(10):1441-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/3968774/pubmed\" id=\"3968774\" target=\"_blank\">",
"        3968774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lieberman P, Nicklas RA, Oppenheimer J, et al, &ldquo;The Diagnosis and Management of Anaphylaxis Practice Parameter: 2010 Update,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2010, 126(3):477-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/20692689/pubmed\" id=\"20692689\" target=\"_blank\">",
"        20692689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Murphy FT, Manown TJ, Knutson SW, et al, &ldquo;Epinephrine-Induced Lactic Acidosis in the Setting of Status Asthmaticus,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1995, 88(5):577-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/7732451/pubmed\" id=\"7732451\" target=\"_blank\">",
"        7732451",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naganobu K, Hasebe Y, Uchiyama Y, et al, &ldquo;A Comparison of Distilled Water and Normal Saline as Diluents for Endobronchial Administration of Epinephrine in the Dog,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2000, 91(2):317-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/10910841/pubmed\" id=\"10910841\" target=\"_blank\">",
"        10910841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peberdy MA, Callaway CW, Neumar RW, et al, &ldquo;Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):768-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/20956225/pubmed\" id=\"20956225\" target=\"_blank\">",
"        20956225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russell JA, Walley KR, Singer J, et al, &ldquo;Vasopressin Versus Norepinephrine Infusion in Patients With Septic Shock,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(9):877-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/18305265/pubmed\" id=\"18305265\" target=\"_blank\">",
"        18305265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sicherer S, Simons F, et al, &ldquo;Self-Injectable Epinephrine for First-Aid Management of Anaphylaxis&rdquo;,",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119(3):638-46.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stiell IG, Hebert PC, Wells GA, et al, &ldquo;Vasopressin Versus Epinephrine for Inhospital Cardiac Arrest: A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 358(9276):105-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/11463411/pubmed\" id=\"11463411\" target=\"_blank\">",
"        11463411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/20956228/pubmed\" id=\"20956228\" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waisman Y, Klein BL, Boenning DA, et al, &ldquo;Prospective Randomized Double-Blind Study Comparing L-Epinephrine and Racemic Epinephrine Aerosols in the Treatment of Laryngotracheitis (Croup),&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(2):302-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/1734400/pubmed\" id=\"1734400\" target=\"_blank\">",
"        1734400",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wenzel V, Krismer AC, Arntz HR, et al, &ldquo;A Comparison of Vasopressin and Epinephrine for Out-of-Hospital Cardiopulmonary Resuscitation. European Resuscitation Council Vasopressor during Cardiopulmonary Resuscitation Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):105-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/4/11337/abstract-text/14711909/pubmed\" id=\"14711909\" target=\"_blank\">",
"        14711909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9116 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11337=[""].join("\n");
var outline_f11_4_11337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085209\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085094\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085093\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085095\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822429\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822430\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085180\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085003\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085143\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471806\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471807\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085063\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085004\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085006\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084974\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085039\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085011\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085012\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299272\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085042\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085046\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085007\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085008\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085010\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335156\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085182\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085149\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085064\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085066\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9116\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9116|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/34/3620?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/59/4020?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/14/40163?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/24/10630?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/20/10568?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_4_11338="Laparoscopic cholecystectomy: Techniques";
var content_f11_4_11338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laparoscopic cholecystectomy: Techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11338/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11338/contributors\">",
"     Preeti Malladi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11338/contributors\">",
"     Nathaniel J Soper, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11338/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11338/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/4/11338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/4/11338/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/4/11338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholecystectomy is one of the most commonly performed abdominal surgical procedures, and in developed countries many are performed laparoscopically. As an example, 90 percent of cholecystectomies in the United States are performed laparoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/1\">",
"     1",
"    </a>",
"    ]. Laparoscopic cholecystectomy is considered the \"gold standard\" for the surgical treatment of gallstone disease. This procedure results in less postoperative pain, better cosmesis, shorter hospital stays and disability from work than open cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. However, the overall serious complication rate in laparoscopic cholecystectomy remains higher than that seen in open cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the technique of laparoscopic cholecystectomy. The diagnosis and overall treatment approach to cholecystitis is discussed elsewhere in detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for laparoscopic cholecystectomy are the same as for open cholecystectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic cholelithiasis with or without complications (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"       \"Treatment of acute cholecystitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link\">",
"       \"Uncomplicated gallstone disease in adults\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Asymptomatic cholelithiasis in patients who are at increased risk for gallbladder carcinoma or gallstone complications (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"       \"Approach to the patient with incidental gallstones\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Acalculous cholecystitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=see_link\">",
"       \"Acalculous cholecystitis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Gallbladder polyps &gt;0.5 cm (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=see_link\">",
"       \"Gallbladder polyps and cholesterolosis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Porcelain gallbladder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39668?source=see_link\">",
"       \"Porcelain gallbladder\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to laparoscopic cholecystectomy are primarily related to anesthetic concerns and include diffuse peritonitis with hemodynamic compromise and uncontrolled bleeding disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/11\">",
"     11",
"    </a>",
"    ]. The inability to tolerate general anesthesia is considered a relative contraindication, but successful laparoscopic cholecystectomy under spinal anesthesia has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there is suspicion of gallbladder cancer, open cholecystectomy should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43399?source=see_link\">",
"     \"Adjuvant treatment for localized, potentially resectable gallbladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relative contraindications are dependent on the surgeon's judgment and experience, but include patients with previous extensive abdominal surgery, cirrhosis with portal hypertension, severe cardiopulmonary disease, active cholangitis, and morbid obesity (",
"    <a class=\"graphic graphic_table graphicRef76254 \" href=\"UTD.htm?28/17/28955\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TIMING OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of surgery will depend upon the patient's overall medical condition and underlying diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cholecystitis &ndash; Patients who present with acute cholecystitis should be placed on antibiotics and the surgery should be performed within 24 hours or as soon as practical after diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"       \"Treatment of acute cholecystitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gallstone pancreatitis &ndash; Patients with gallstone pancreatitis has a high risk of recurrence within 30 days of their attack and therefore should undergo cholecystectomy during their index hospitalization after their symptoms resolve. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=see_link\">",
"       \"Treatment of acute pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obstructive jaundice &ndash; A history of pancreatitis or jaundice raises the likelihood of common bile duct (CBD) stones. Patients with isolated obstructive jaundice with or without cholangitis should either have their CBD cleared with urgent endoscopic retrograde cholangiopancreatography (ERCP) preoperatively or with cholangiography and laparoscopic common duct exploration at the time of surgery . If ERCP is successful, the patient should electively be scheduled for cholecystectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"       \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical comorbidities &ndash; Identification of bleeding diatheses and poor cardiopulmonary reserve will help identify patients who may not tolerate pneumoperitoneum or will have higher likelihood for conversion to open operation. In patients with multiple comorbidities or acute medical problems (such as a recent myocardial infarction), a trial of antibiotics with consideration for a percutaneous cholecystostomy tube with delayed laparoscopic cholecystectomy in six to eight weeks may be preferable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"       \"Treatment of acute cholecystitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing in patients being evaluated for acute cholecystitis typically includes a complete blood count, liver enzymes, amylase, and lipase.",
"   </p>",
"   <p>",
"    Elevations in the serum total bilirubin and alkaline phosphatase concentrations are",
"    <strong>",
"     not",
"    </strong>",
"    common in uncomplicated cholecystitis, since biliary obstruction is limited to the gallbladder; if present, they should raise concerns about complicating conditions such as cholangitis, choledocholithiasis, or the Mirizzi syndrome (a gallstone impacted in the distal cystic duct causing extrinsic compression of the common bile duct). However, mild elevations have been reported even in the absence of these complications, and may be due to the passage of small stones, sludge, or pus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For young otherwise healthy patients with gallstones but no evidence of pericholecystic inflammation or bile duct dilation, additional preoperative lab testing is not routinely necessary, unless a new clinical event has occurred such as significant pain, fever, or jaundice or the physical exam suggests that an abnormality is present. An electrocardiogram or chest radiograph is obtained as appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link&amp;anchor=H10#H10\">",
"     \"Preoperative medical evaluation of the healthy patient\", section on 'Laboratory evaluation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    For patients with complicated biliary tract disease, abnormal tests (eg, liver function tests, amylase, lipase) should be repeated to serve as a baseline for postoperative comparison. Coagulation tests are not routinely needed but may be obtained if there is a reason to believe an abnormality may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography (US) of the right upper quadrant establishes the diagnosis of gallstones or abnormalities of the gallbladder wall. The US may also demonstrate CBD dilatation, stones, or evidence of acute inflammation of the gallbladder. Nuclear cholescintigraphy may be useful in cases in which the diagnosis remains uncertain after ultrasonography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21992?source=see_link\">",
"     \"Ultrasonography of the hepatobiliary tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnetic resonance cholangiopancreatography (MRCP) may be useful to evaluate the common duct in patients with mild elevations of their transaminases or mild CBD dilatation on US. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Endoscopic retrograde cholangiopancreatography (ERCP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient has a dilated CBD, CBD stones, or jaundice, consideration should be given to a preoperative ERCP with clearing of the stones followed by laparoscopic cholecystectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=see_link\">",
"     \"Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114901495\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should have the procedure described in detail with communication of the possibility of conversion to an open procedure. The patients should be informed about the risks of bile duct injury, bowel injury, vascular injury, and re-operation or need for postoperative ERCP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing elective cholecystectomy who are at low risk of infection do not need to receive prophylactic antibiotics perioperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. For biliary tract surgery, prophylaxis is recommended in patients at high risk for infection, defined as age greater than 70 years, acute cholecystitis, a nonfunctioning gallbladder, obstructive jaundice, and common bile duct stones (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 2",
"    </a>",
"    ). The recommended antibiotics are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 2 g intravenously) or, in patients allergic to penicillins and cephalosporins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus one of the following:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    . In patients who have been started on antibiotics due to biliary tract infection, antibiotics are re-dosed prior to surgery (",
"    <a class=\"graphic graphic_table graphicRef67894 \" href=\"UTD.htm?7/21/7517\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of acute cholecystitis\", section on 'Antibiotics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link&amp;anchor=H9#H9\">",
"     \"Acute cholangitis\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114901628\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;For visualization, an angled laparoscope is recommended (typically a 30 degree) to facilitate alternative views of the operative field. Two grasping forceps are needed, one for the assistant and one for the surgeon. Toothed graspers may be helpful for particularly thick-walled, edematous gallbladders.",
"   </p>",
"   <p>",
"    For the assistant, a ratchet mechanism, which locks the grasper closed, will help alleviate fatigue. A fine curved dissecting forceps can be used to dissect around delicate structures. Scissors are important for transection, and a hook or spatula with monopolar cautery is used for dissection. A clip applier is typically used to seal the cystic duct and artery.",
"   </p>",
"   <p>",
"    Other tools that should be available include a",
"    <span class=\"nowrap\">",
"     suction/irrigation",
"    </span>",
"    device, cholangiogram catheters (4-5 French), retrieval bag, endoscopic ligating loops, appropriate trocars (we use a Hasson [blunt-tipped trocar for open insertion], 11 mm, and 2 X 5 mm), endoscopic needle holders, and a Veress needle (if percutaneous technique used).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Safety checklist",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consent includes the possibility of conversion to an open procedure and the risks of bile duct injury, bowel injury, vascular injury, and the potential need for re-operation or ERCP.",
"     </li>",
"     <li>",
"      Anesthetic concerns specific to the patient have been reviewed.",
"     </li>",
"     <li>",
"      Proper instruments, staplers, and drains are available.",
"     </li>",
"     <li>",
"      Prophylactic antibiotics have been administered.",
"     </li>",
"     <li>",
"      Imaging studies have been reviewed and are displayed in the operating room.",
"     </li>",
"     <li>",
"      Appropriate deep venous thromboembolism (DVT) prophylaxis has been ordered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic cholecystectomy is performed under general anesthesia. The generally short duration of the procedure minimizes the need for gastric decompression or placement of a urinary bladder catheter. The following sections describe the technique of a standard laparoscopic cholecystectomy. The technical details such as suture choice presented here reflect the author's preferences and are not meant to imply that these are requirements for successful surgical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is placed in a supine position on the operating room table. During abdominal access and insufflation of the abdomen, the table can remain flat. Thereafter, the patient should be placed in a reverse Trendelenburg position with left side down to allow gravity to aid with exposure of the gallbladder (",
"    <a class=\"graphic graphic_figure graphicRef52727 \" href=\"UTD.htm?25/19/25910\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In North American positioning, the patient is placed supine on the operating room table. The surgeon stands on the patient's left and the assistant on the right. The camera operator stands to the surgeon's left. The primary video monitor should be placed on the right at the level of the shoulder. A second monitor can be placed on the surgeon's right.",
"     </li>",
"     <li>",
"      In the European style, the patient is placed supine with legs abducted, and the surgeon stands between the legs. The camera operator is positioned to the patient's left, and the assistant to the right (",
"      <a class=\"graphic graphic_figure graphicRef52727 \" href=\"UTD.htm?25/19/25910\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114901272\">",
"    <span class=\"h2\">",
"     Abdominal access",
"    </span>",
"    &nbsp;&mdash;&nbsp;General information about access techniques in laparoscopic surgery is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"     \"Abdominal access techniques used in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the umbilical trocar is placed, the laparoscope can be introduced and the abdomen inspected. For laparoscopic cholecystectomy, three to four ports are typically placed. Emerging techniques for abdominal access for cholecystectomy include a single-site port approach and natural orifice transluminal endoscopic surgery (NOTES). The techniques are discussed briefly below as they pertain to cholecystectomy. A more detailed discussion is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link&amp;anchor=H376701701#H376701701\">",
"     \"Abdominal access techniques used in laparoscopic surgery\", section on 'Single-incision surgery (SIS)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2103?source=see_link\">",
"     \"Natural orifice transluminal endoscopic surgery (NOTES)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The advantage of single-site surgery compared with NOTES is that standard laparoscopic instruments and skills are used and the learning curve is not as steep. As a result, the single-site approach has been more readily implemented and has demonstrated a high degree of acceptance. However, the in-line instrumentation in single-site surgery renders retraction and dissection techniques more difficult compared with a conventional approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Conventional port placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three more ports are typically placed under direct vision (",
"    <a class=\"graphic graphic_figure graphicRef50974 \" href=\"UTD.htm?33/14/34018\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65844 \" href=\"UTD.htm?21/17/21778\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The assistant's 5 mm trocar is usually placed at the mid-axillary line halfway between the costal margin and the anterior superior iliac spine. A grasping forceps is placed to grasp the fundus of the gallbladder and retract it and the liver superiorly.",
"     </li>",
"     <li>",
"      A second 5 or 10 mm port, which will accommodate the surgeon's right hand instruments, is placed in the high",
"      <span class=\"nowrap\">",
"       epigastric/subxiphoid",
"      </span>",
"      region just to the right of the falciform ligament. The size of the trocar depends on the size of the clip applier to be used. This trocar is directed toward the gallbladder neck.",
"     </li>",
"     <li>",
"      A third trocar for the surgeon's left hand instruments is placed at the right midclavicular line just below the liver edge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359875832\">",
"    <span class=\"h3\">",
"     Single-site port approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;A laparoscopic single-site approach uses one transabdominal incision rather than multiple sites for trocar placement (",
"    <a class=\"graphic graphic_picture graphicRef64522 \" href=\"UTD.htm?14/19/14643\">",
"     picture 1",
"    </a>",
"    ). The procedure is designed to decrease abdominal wall trauma and improve cosmesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The trocars are placed through the abdominal incision using a multi-instrument port or closely spaced adjacent each other through the periumbilical incision. Sutures can be passed through the abdominal wall and through the gallbladder fundus to aid with retraction. The incision is also used as the specimen extraction site.",
"   </p>",
"   <p>",
"    Single-site surgery is most commonly applied to laparoscopic cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/21-29\">",
"     21-29",
"    </a>",
"    ]. Randomized trials have found the approach feasible and safe, but outcomes are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. One trial that randomly assigned 40 patients with symptomatic cholelithiasis to standard laparoscopic cholecystectomy versus single-site surgery, reported lower abdominal pain and shoulder pain scores in the single-site group, but no differences in nausea, vomiting, or postoperative complications. The single-site group had significantly increased operative times (49 versus 37 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/25\">",
"     25",
"    </a>",
"    ]. A larger trial also found improved postoperative pain profiles and lower analgesic requirements as well as improved postoperative quality of life (QOL) measures and better body image and scar scores compared with a conventional approach; however, operative costs were higher for the single-site approach [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/27\">",
"     27",
"    </a>",
"    ]. In this trial, two of the single-site procedures were converted to a two-port approach but no open conversions were required. No differences were seen in port-site",
"    <span class=\"nowrap\">",
"     seroma/hematoma.",
"    </span>",
"    In contrast, another trial did not find any differences in pain scores, QOL measures, or cosmesis, but noted a significantly longer operative time for single-site surgery, and more complications overall [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/28\">",
"     28",
"    </a>",
"    ]. Another study that specifically compared the costs of the two techniques found they were comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with any new surgical technique, adherence to safe surgical principles is important. Meticulous dissection with clear, unequivocal identification of structures is required, and there should be a low threshold to convert to standard laparoscopy. More data from the randomized trials will allow a better determination of the true benefits of single access cholecystectomy. Longer follow-up is needed to assess whether the larger incision will lead to an increased incidence of incisional hernias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359875385\">",
"    <span class=\"h3\">",
"     Natural orifice transluminal endoscopic surgery (NOTES)",
"    </span>",
"    &nbsp;&mdash;&nbsp;To maximize the potential benefits of minimally invasive surgery, a new concept in surgery, natural orifice transluminal endoscopic surgery (NOTES), has been developed. The theoretical advantage of NOTES surgery is scarless intraperitoneal surgery with minimal patient discomfort. Still under investigation, NOTES has many technical challenges and its application has been limited to a few centers worldwide. These centers have performed cholecystectomies using endoscopic instrumentation through transgastric and transvaginal approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2103?source=see_link\">",
"     \"Natural orifice transluminal endoscopic surgery (NOTES)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Gallbladder exposure and dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assistant using the ratcheted toothed grasper pushes the fundus of the gallbladder superiorly and laterally to reveal the infundibulum and porta hepatis.",
"   </p>",
"   <p>",
"    If the gallbladder is very distended, it can be difficult to grasp. Aspirating it with a large bore needle or a sharp tipped suction device facilitates purchase by the grasper. The grasper (or stitch or ligating loop) can then be used to close the hole to prevent further spillage of content.",
"   </p>",
"   <p>",
"    Occasionally, adhesions to the duodenum, omentum, or colon from previous surgery or inflammation impair this exposure. The surgeon can take down these adhesions safely by grasping the adhesions at their attachment high on the gallbladder and stripping them down bluntly towards the infundibulum. Minimal electrocautery should be used in order to reduce the risk of thermal injury to the adjacent bowel (",
"    <a class=\"graphic graphic_figure graphicRef52727 \" href=\"UTD.htm?25/19/25910\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dissection of the hepatocystic triangle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important consideration in a cholecystectomy is the clear identification of the cystic artery and duct prior to division.",
"   </p>",
"   <p>",
"    To this end, a thorough dissection of the hepatocystic triangle, bounded by the gallbladder wall, cystic duct, and common hepatic duct, to obtain the \"critical view of safety\" is a key step (discussed below) (",
"    <a class=\"graphic graphic_figure graphicRef66207 \" href=\"UTD.htm?25/3/25649\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/34\">",
"     34",
"    </a>",
"    ]. The surgeon grasps the infundibulum with the left hand forceps and retracts inferiorly and laterally to open the angle between the cystic duct and common duct. This instrument is used to provide retraction in various angles to give anterior and posterior exposure of the triangle.",
"   </p>",
"   <p>",
"    Occasionally, a large stone at the gallbladder neck prevents grasping of the infundibulum. This scenario can be managed by dislodging and \"milking\" the stone back up into the gallbladder body or by placing a stitch into the infundibulum and using that for retraction. The dissection of the junction of the gallbladder and cystic duct begins by the surgeon gently stripping the peritoneum starting high on the gallbladder. Keeping the dissection on a known safe structure (the gallbladder) to develop visualization of the unknown structures is an important principle.",
"   </p>",
"   <p>",
"    The postero-lateral aspect of the gallbladder is the safest area for initial dissection and can be exposed by retracting the infundibulum superior and medial. The surgeon can use minimal cautery or blunt dissection to incise the superficial layer of peritoneum attaching the gallbladder neck to the liver in order to allow further retraction of the infundibulum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Critical view of safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior and posterior dissection continues with alternating infero-lateral and supero-medial retraction of the neck until the gallbladder is dissected away from the liver, creating a \"window\" crossed by two structures: the cystic duct and artery. This is the \"critical view of safety\" that should be achieved prior to clipping or dividing any tubular structures (",
"    <a class=\"graphic graphic_figure graphicRef66207 \" href=\"UTD.htm?25/3/25649\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no need to dissect down to the cystic duct-common bile duct junction unless the cystic duct is very short. The cystic artery should be dissected in a similar fashion. Calot's node, or cystic duct lymph node, is usually encountered adjacent and anterior to the artery and can be a useful landmark. Electrocautery may be needed for hemostasis before the node can be bluntly swept down (",
"    <a class=\"graphic graphic_figure graphicRef52727 \" href=\"UTD.htm?25/19/25910\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The surgeon should be aware of certain anatomic variations in order to avoid misidentification of structures. A common anomaly is the right hepatic artery looping onto the infundibulum and being mistaken for the cystic artery. A short cystic duct is also seen quite frequently and could drain into the right hepatic duct, the common duct, or a low-lying aberrant right sectoral duct. In the presence of severe, acute, or chronic inflammation, or with a large stone in the neck of the gallbladder, the infundibulum may be \"tethered\" to the hepatic duct, which may lead the surgeon to misidentify the common bile duct for the cystic duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Division of cystic artery and cystic duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the cystic duct and artery are fully dissected, a clip is placed laterally on the cystic duct adjacent the gallbladder. The cystic duct is incised distal to the clip and the side of a closed graspers sweeps the bile duct towards the ductotomy to assess cystic duct patency. Then, using a curved dissector, the cystic duct is \"milked\" retrograde by compressing it towards the ductotomy in order to palpate stones, bring out any small residual stones, and to assess for free flow of bile. Once this is accomplished, two more clips are placed distal to the ductotomy.",
"   </p>",
"   <p>",
"    Both jaws of the clips should be visualized and clearly encompass the duct in order to avoid inadvertent injuries to structures behind the clips and to ensure complete duct closure. Then the duct is fully transected with scissors.",
"   </p>",
"   <p>",
"    Electrocautery should not be used since the electrical current can be transmitted to the clips and cause delayed necrosis of the stump. The artery is clipped and divided in a similar fashion. The anterior branch of the cystic artery is commonly mistaken for the main cystic artery; therefore, the tissue behind the clipped artery should be dissected to ensure that there is no posterior branch, which can cause troublesome bleeding during the subsequent removal of the gallbladder. The clipped stumps should be inspected for adequacy of closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Evaluation for choledocholithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is any concern for choledocholithiasis (elevated bilirubin, dilated duct) or uncertain anatomy, the common bile duct should be imaged intraoperatively. This should occur after the first clip is placed on the cystic duct. Intraoperative cholangiogram (IOC) or laparoscopic ultrasound (LUS) may be performed. Once stones are found and retrieved, a completion cholangiogram should be obtained to verify clearance (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59179 \" href=\"UTD.htm?27/63/28657\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Intraoperative cholangiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative cholangiography (IOC) should be accomplished before beginning CBD exploration. The catheter for IOC is placed after careful dissection achieves the critical view of safety (",
"    <a class=\"graphic graphic_figure graphicRef66207 \" href=\"UTD.htm?25/3/25649\">",
"     figure 4",
"    </a>",
"    ). The technique of IOC and common bile duct exploration are discussed elsewhere in detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6440?source=see_link&amp;anchor=H813094#H813094\">",
"     \"Common bile duct exploration\", section on 'Intraoperative cholangiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Laparoscopic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;LUS may alternatively be performed to evaluate the CBD. It requires a certain comfort and skill level. A prospective multicenter study of 209 patients showed that in experienced hands, LUS can be equivalent to an IOC in detecting stones and can be performed almost 50 percent faster [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/36\">",
"     36",
"    </a>",
"    ]. On the other hand, IOC is better at detecting intrahepatic anatomy and anatomic anomalies of the biliary tree [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/36\">",
"     36",
"    </a>",
"    ]. A retrospective study of 1381 patients who underwent laparoscopic cholecystectomy at five centers showed that LUS successfully delineated the bile duct anatomy in 98 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Dissection of gallbladder from liver bed",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assistant places continual cephalad traction on the gallbladder fundus while the surgeon alternates medial and lateral anteroposterior traction on the infundibulum with the left hand grasper. This retraction exposes and maintains tension on the plane of tissue attaching the gallbladder to the liver. This tissue is gently divided using a hook or spatula cautery in a sweeping motion. This dissection continues from infundibulum to fundus, and bleeding should be minimal if dissection is performed in the correct plane. Prior to completely detaching the gallbladder, the liver should be inspected for areas of bleeding or bile leakage. The right upper quadrant is irrigated, and then the gallbladder is fully released.",
"   </p>",
"   <p>",
"    Occasionally, persistent minimal bile leakage occurs from the liver bed. This leak may be from a transected duct of Luschka or, more likely, from a superficial duct within the liver that was unroofed during the dissection. If the end of the duct can be grasped then the duct should be clipped. Otherwise, one may perform intracorporeal suturing of the opening of the duct, or simply leave a closed suction drain to control the leak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Gallbladder extraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The umbilical incision is the ideal location for extracting the gallbladder. The umbilical incision has no muscle layers and is easy to extend with minimal pain and cosmetic sequelae. To limit bile contamination of the abdomen and wound, an extraction bag is used when the gallbladder is acutely inflamed and friable or when there was inadvertent perforation of the gallbladder. Any remaining loose stones can be placed in the bag as well. The laparoscope is transferred to the subxiphoid position, and the bag or a large toothed grasper is positioned within the umbilical trocar.",
"   </p>",
"   <p>",
"    The gallbladder is placed into the bag or the infundibulum is grasped with the forceps. The trocar is removed, and the gallbladder is withdrawn through this incision under laparoscopic vision. If the gallbladder is very large or contains large stones, the fascial incision may need to be stretched or enlarged. Once the gallbladder is removed, the right upper quadrant can be irrigated if necessary, and the other trocars can be removed under direct vision while allowing escape of CO2. The umbilical fascia is then closed with the stay sutures originally placed.",
"   </p>",
"   <p>",
"    The specimen can also be retrieved through the subxiphoid port site. Some surgeons feel that the subxiphoid site may be better for specimen extraction as the subxiphoid site has a lower likelihood of hernia formation; however, formal study of this has not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The skin is closed with subcuticular absorbable stitches and with Steri-Strips. The incisions are infused with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    for postoperative analgesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhotic patients with portal hypertension pose a particular challenge to the surgeon. They are at higher risk for any surgical procedure, and preoperative preparation is critical for good outcomes. These patients should have their liver function optimized prior to an elective cholecystectomy. Some may need replacement of clotting factors to minimize intraoperative bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=see_link\">",
"     \"Assessing surgical risk in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Care should be taken when placing trocars to avoid the \"caput medusa\" of large collateral vessels in the abdominal wall. The cirrhotic liver itself is usually quite hard and easily injured just with retraction. Bleeding from a cirrhotic liver is difficult to control, so remaining in the correct plane during dissection of the gallbladder from the liver is particularly important.",
"   </p>",
"   <p>",
"    Various hemostatic agents and energy sources (the argon cautery device can be quite useful) need to be available in case bleeding develops. Particular care should be taken in making water-tight closures for all incisions to minimize perioperative ascitic leak [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally accepted that elective laparoscopic cholecystectomy for biliary colic should be deferred until after pregnancy, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=see_link\">",
"     \"Intercurrent hepatobiliary disease during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If surgery must be performed, the trocars may need to be placed higher in the abdomen due to the enlarged uterus. The CO2 insufflation should be kept at the lowest level in order to keep a working space. If CBD imaging is necessary, LUS should be used in place of IOC to limit radiation exposure. Preoperative obstetric consultation and perioperative fetal monitoring are advisable [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/40\">",
"     40",
"    </a>",
"    ]. Details of proper positioning for surgery and management of pregnant women undergoing surgery are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=see_link\">",
"     \"Laparoscopic surgery in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laparoscopic surgery can be performed safely during pregnancy by experienced surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/41\">",
"     41",
"    </a>",
"    ]. A retrospective cross-sectional analysis of hospital discharge data from the Healthcare Cost and Utilization Project-Nationwide Inpatient Sample database was conducted to study outcomes after cholecystectomy during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/42\">",
"     42",
"    </a>",
"    ]. In this study, 9714 pregnant women who underwent cholecystectomy experienced significantly higher surgical, maternal, and fetal complication rates, length of stay, and costs with open cholecystectomy as compared with laparoscopic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/42\">",
"     42",
"    </a>",
"    ]. This may reflect the reasons for choosing an open cholecystectomy such as prior surgery, gangrenous gallbladder, or trimester of pregnancy, rather than a true difference in complication rates between the procedures however. High volume surgeons, defined as those providers above the 75th percentile, based on the annual number of cholecystectomies performed, had significantly lower rates of surgical complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the obese patient has a thick abdominal wall, trocar placement is particularly important. The thickness of the wall inhibits the mobility of the trocars so they should be placed at the angle most likely to be used during the cholecystectomy. Longer trocars may be needed to traverse the abdominal wall in order to avoid trocar displacement and subsequent insufflation within the abdominal wall and subcutaneous emphysema. Longer instruments may be required to reach the gallbladder, and the initial umbilical trocar may need to be placed at a supraumbilical position. The surgeon should not hesitate to place additional trocars if needed. Although laparoscopy may be more challenging in the morbidly obese patient, it may offer advantages specific to these patients such as decreased wound infection, DVT, and incisional hernias, which may make laparoscopy the preferred approach [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Gangrenous cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic cholecystectomy can be done safely in the setting of acute or gangrenous cholecystitis and should be done as soon as possible to fall within the \"golden period\" within 72 hours when edema is the primary manifestation of the inflammation. If the patient presents in a delayed fashion (&gt;72 hours from onset of symptoms), the surgery can be performed if there are no contraindications to an open procedure, as conversion is a significant risk. In the face of acute cholecystitis with multiple co-morbidities, it may be preferable to treat with IV antibiotics and possibly percutaneous drainage, with subsequent laparoscopic cholecystectomy six to eight weeks later. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different techniques may be needed when a gangrenous gallbladder or dense inflammation is encountered. A \"top down\" approach to dissection of the gallbladder as in an open procedure may be necessary to appreciate the anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The surgeon may perform subtotal cholecystectomy by transecting the infundibulum as close to the cystic duct as possible and extracting all stones. The gallbladder neck is then sewn closed, if possible, and a drain is placed in the gallbladder bed. This transection of an edematous, friable wall may be facilitated by using the ultrasonic shears. In a gallbladder densely adherent to the liver where the plane between the two is obliterated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in the presence of portal hypertension, it may be preferable to leave the back wall of the gallbladder intact and fully cauterize its mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/47\">",
"     47",
"    </a>",
"    ]. Blunt dissection with a suction irrigator or laparoscopic peanut is particularly useful in defining anatomy around a grossly inflamed duct.",
"   </p>",
"   <p>",
"    An active suction drain should be left beneath the liver if there is any question regarding the integrity of the cystic duct closure or any suspicion of bile leakage from the gallbladder bed. We do not place a drain to monitor for bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Large cystic duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally the cystic duct is quite enlarged and inflamed and standard clips are inadequate to seal the duct. In these instances, preformed suture loops may be helpful in completely closing the duct. Some surgeons may suture ligate the cystic duct stump using intracorporeal suturing, while others use extracorporeal knot tying in order to control the duct before transecting it. Rarely, an endoscopic stapler is used to transect an unusually large cystic duct after assuring that the structure is not, in fact, the common bile duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major complications, including vascular injury, bowel perforation, mesenteric injury, and bile duct injuries, often require immediate laparotomy. A laparoscopic operation should be converted to an open procedure if the surgeon encounters a situation demanding manual palpation and direct vision for correction. Surgeons should convert to open operations without hesitation if the need arises. Open cholecystectomy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36489?source=see_link\">",
"     \"Open cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversion to an open operation is indicated for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhage",
"     </li>",
"     <li>",
"      Unusual or confusing anatomy",
"     </li>",
"     <li>",
"      Failure to progress laparoscopically in a timely fashion",
"     </li>",
"     <li>",
"      Bowel perforation or major injury to the bile ducts",
"     </li>",
"     <li>",
"      Potentially resectable gallbladder cancer",
"     </li>",
"     <li>",
"      Common bile duct stones that cannot be removed laparoscopically or endoscopically (due to Billroth II anatomy, previously failed ERCP, or lack of an experienced endoscopist).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications of laparoscopic cholecystectomy, particularly common bile duct injury, are discussed in detail separately, but will be summarized here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6232?source=see_link\">",
"     \"Repair of common bile duct injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gallbladder perforation &ndash; During the dissection of the gallbladder, the surgeon may enter the gallbladder inadvertently, causing spillage of bile",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stones. The hole in the gallbladder can be closed by incorporating it within the grasping forceps or may be sutured closed to prevent further spillage. The bile should be suctioned and irrigated. Bile spillage has not been shown to increase postoperative infections [",
"      <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/48\">",
"       48",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The stones should be extracted if at all possible. Large stone graspers are helpful in performing this task. Stones, particularly pigment stones, which harbor bacteria, can increase the risk of postoperative infection if left in the abdomen or port site [",
"      <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/49-52\">",
"       49-52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vascular injury &ndash; If a trocar impales a major blood vessel, the trocar should not be removed but allowed to tamponade the vessel while an immediate laparotomy is preformed. Another site of hemorrhage is from lacerated abdominal wall vessels; therefore, trocars should be visualized with the laparoscope when removed. Bleeding from these sites can usually be controlled with cautery, Foley catheter balloon tamponade, or a figure of eight stitch placed directly or with a suture passer.",
"     </li>",
"     <li>",
"      Bowel injury &ndash; Bowel injuries should be marked and closely observed during and at the end of the case. If leakage occurs, the injury can be repaired laparoscopically or in an open fashion through extension of the umbilical incision. Then the procedure can proceed laparoscopically.",
"     </li>",
"     <li>",
"      Bile duct injuries &ndash; Major bile duct injuries should be immediately repaired if recognized. There is interest in using fluorescent imaging with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"       indocyanine green",
"      </a>",
"      to define biliary anatomy and prevent bile duct injuries. There is not enough evidence to recommend this, but the technique appears promising [",
"      <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/53,54\">",
"       53,54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some bile duct injuries may be unrecognized at the time of surgery and present in a delayed fashion. These should all be referred to an experienced biliary surgeon, since the greatest chance for successful repair is at the first operation. If the surgeon is at another facility, the patient should be externally drained prior to transfer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6232?source=see_link\">",
"       \"Repair of common bile duct injuries\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     ROUTINE POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an uncomplicated elective laparoscopic cholecystectomy, patients can drink clear liquids once awake from anesthesia and their diet can be advanced as tolerated.",
"   </p>",
"   <p>",
"    Most otherwise healthy, reliable patients with good home support can leave the hospital within six hours after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients with comorbidities, elderly patients, those who had complications, or required large amounts of anesthesia should be kept overnight for observation.",
"   </p>",
"   <p>",
"    The patient should have no activity restriction unless the umbilical incision was particularly large. Then, limited heavy lifting for a few weeks is advisable. Most patients are able to return to work within one week. Patients follow up in clinic two to four weeks after their operation.",
"   </p>",
"   <p>",
"    Most patients have some abdominal pain that resolves within two to three days after surgery and can be managed with analgesics. Occasionally, patients have referred shoulder and neck pain from the CO2 insufflation causing diaphragmatic irritation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications that occur with laparoscopic cholecystectomy, including bile duct injury, bile leaks, bleeding, and bowel injury result in part from patient selection, surgical inexperience, and the technical constraints that are inherent to the minimally invasive approach. These are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other adverse outcomes, such as retained common bile duct stones (incidence of around 10 percent), postcholecystectomy syndromes, and misdiagnoses (sphincter of Oddi dysfunction) occur with the same frequency with both laparoscopic and open cholecystectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H689178094\">",
"    <span class=\"h2\">",
"     Postcholecystectomy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postcholecystectomy syndrome (PCS) is a complex of heterogeneous symptoms including persistent abdominal pain and dyspepsia that recur and persist after cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. PCS is defined as \"early\" if it occurs in the postoperative period and \"late\" if it occurs months or years after surgery. The symptoms of pain and dyspepsia referred to as PCS can be caused by a wide spectrum of conditions, both biliary and extrabiliary. About half of the patients with PCS are found to have biliary, pancreatic, or gastrointestinal disorders, while the remaining patients have extraintestinal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/4/11338/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biliary causes of PCS include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early PCS can be due to biliary injury, retained cystic duct, or common bile duct stones.",
"     </li>",
"     <li>",
"      Late PCS can be due to recurrent CBD stones, bile duct strictures, an inflamed cystic duct or gallbladder remnant, papillary stenosis, or biliary dyskinesia. Biliary dyskinesia refers to motor forms of sphincter of Oddi dysfunction. Sphincter of Oddi dysfunction can be evaluated with sphincter of Oddi manometry, which is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extrabiliary causes of PCS include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gastrointestinal causes such as irritable bowel syndrome, pancreatitis, pancreatic tumors, pancreas divisum, hepatitis, peptic ulcer disease, mesenteric ischemia, diverticulitis, or esophageal diseases",
"     </li>",
"     <li>",
"      Extraintestinal causes such as intercostal neuritis, wound neuroma, coronary artery disease, or psychosomatic disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment for PCS is tailored to the specific cause of the symptoms. Diagnosis of the underlying problem causing PCS usually requires imaging to look for retained or recurrent stones or identify a bile duct leak, stricture, or transection. This can be accomplished in most cases with ultrasound",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computed tomography (CT) scanning followed by direct cholangiography or magnetic resonance cholangiopancreatography (MRCP). MRCP provides a noninvasive alternative to direct cholangiography for evaluation of the biliary tract. The approach to the diagnosis of choledocholithiasis or biliary injury is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link&amp;anchor=H972627978#H972627978\">",
"     \"Approach to the patient with suspected choledocholithiasis\", section on 'Imaging tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link&amp;anchor=H10#H10\">",
"     \"Complications of laparoscopic cholecystectomy\", section on 'Diagnosis and management of biliary injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=see_link\">",
"       \"Patient information: Gallbladder removal (cholecystectomy) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laparoscopic cholecystectomy is considered the \"gold standard\" for the surgical treatment of gallstone disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for laparoscopic cholecystectomy are the same as for open cholecystectomy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal timing of surgery will depend on the patient's overall medical condition and underlying diagnosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Timing of surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Liver function tests (LFTs) should be obtained preoperatively. Elevation in the serum total bilirubin and alkaline phosphatase concentrations should raise concerns about complicating conditions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasonography (US) of the right upper quadrant establishes the diagnosis of gallstones, abnormalities of the gallbladder wall, common bile duct (CBD) dilatation, stones, or evidence of acute inflammation of the gallbladder. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a patient has a dilated CBD, CBD stones, or jaundice, a preoperative endoscopic retrograde cholangiopancreatography (ERCP) or intraoperative cholangiography and possible common bile duct exploration should be performed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoperative discussion with the patient should include the possibility of conversion to an open procedure. The patients should be informed about the risks of bile duct injury, bowel injury, vascular injury, and re-operation or need for postoperative ERCP. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important consideration in a cholecystectomy is the clear identification of the cystic artery and duct prior to division. The \"critical view of safety\" should be achieved prior to clipping or dividing any tubular structures. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A laparoscopic operation should be converted to an open procedure if the surgeon encounters a situation demanding manual palpation and direct vision for correction. Surgeons should convert to open operations without hesitation if the need arises. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Intraoperative complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/1\">",
"      Csikesz NG, Singla A, Murphy MM, et al. Surgeon volume metrics in laparoscopic cholecystectomy. Dig Dis Sci 2010; 55:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/2\">",
"      Soper NJ, Stockmann PT, Dunnegan DL, Ashley SW. Laparoscopic cholecystectomy. The new 'gold standard'? Arch Surg 1992; 127:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/3\">",
"      Schirmer BD, Edge SB, Dix J, et al. Laparoscopic cholecystectomy. Treatment of choice for symptomatic cholelithiasis. Ann Surg 1991; 213:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/4\">",
"      Wiesen SM, Unger SW, Barkin JS, et al. Laparoscopic cholecystectomy: the procedure of choice for acute cholecystitis. Am J Gastroenterol 1993; 88:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/5\">",
"      Wilson RG, Macintyre IM, Nixon SJ, et al. Laparoscopic cholecystectomy as a safe and effective treatment for severe acute cholecystitis. BMJ 1992; 305:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/6\">",
"      Rattner DW, Ferguson C, Warshaw AL. Factors associated with successful laparoscopic cholecystectomy for acute cholecystitis. Ann Surg 1993; 217:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/7\">",
"      Johansson M, Thune A, Nelvin L, et al. Randomized clinical trial of open versus laparoscopic cholecystectomy in the treatment of acute cholecystitis. Br J Surg 2005; 92:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/8\">",
"      Yamashita Y, Takada T, Kawarada Y, et al. Surgical treatment of patients with acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/9\">",
"      Vollmer CM Jr, Callery MP. Biliary injury following laparoscopic cholecystectomy: why still a problem? Gastroenterology 2007; 133:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/10\">",
"      Khan MH, Howard TJ, Fogel EL, et al. Frequency of biliary complications after laparoscopic cholecystectomy detected by ERCP: experience at a large tertiary referral center. Gastrointest Endosc 2007; 65:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/11\">",
"      Keus F, Broeders IA, van Laarhoven CJ. Gallstone disease: Surgical aspects of symptomatic cholecystolithiasis and acute cholecystitis. Best Pract Res Clin Gastroenterol 2006; 20:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/12\">",
"      Sinha R, Gurwara AK, Gupta SC. Laparoscopic cholecystectomy under spinal anesthesia: a study of 3492 patients. J Laparoendosc Adv Surg Tech A 2009; 19:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/13\">",
"      Steinert R, Nestler G, Sagynaliev E, et al. Laparoscopic cholecystectomy and gallbladder cancer. J Surg Oncol 2006; 93:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/14\">",
"      Lo CM, Liu CL, Fan ST, et al. Prospective randomized study of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Ann Surg 1998; 227:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/15\">",
"      Gurusamy KS, Samraj K, Fusai G, Davidson BR. Early versus delayed laparoscopic cholecystectomy for biliary colic. Cochrane Database Syst Rev 2008; :CD007196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/16\">",
"      Gurusamy K, Samraj K, Gluud C, et al. Meta-analysis of randomized controlled trials on the safety and effectiveness of early versus delayed laparoscopic cholecystectomy for acute cholecystitis. Br J Surg 2010; 97:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/17\">",
"      Fry DE. Surgical site infections and the surgical care improvement project (SCIP): evolution of national quality measures. Surg Infect (Larchmt) 2008; 9:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/18\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/19\">",
"      Sharma N, Garg PK, Hadke NS, Choudhary D. Role of prophylactic antibiotics in laparoscopic cholecystectomy and risk factors for surgical site infection: a randomized controlled trial. Surg Infect (Larchmt) 2010; 11:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/20\">",
"      Choudhary A, Bechtold ML, Puli SR, et al. Role of prophylactic antibiotics in laparoscopic cholecystectomy: a meta-analysis. J Gastrointest Surg 2008; 12:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/21\">",
"      Hodgett SE, Hernandez JM, Morton CA, et al. Laparoendoscopic single site (LESS) cholecystectomy. J Gastrointest Surg 2009; 13:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/22\">",
"      Marks J, Tacchino R, Roberts K, et al. Prospective randomized controlled trial of traditional laparoscopic cholecystectomy versus single-incision laparoscopic cholecystectomy: report of preliminary data. Am J Surg 2011; 201:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/23\">",
"      Philipp SR, Miedema BW, Thaler K. Single-incision laparoscopic cholecystectomy using conventional instruments: early experience in comparison with the gold standard. J Am Coll Surg 2009; 209:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/24\">",
"      Ponsky TA. Single port laparoscopic cholecystectomy in adults and children: tools and techniques. J Am Coll Surg 2009; 209:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/25\">",
"      Tsimoyiannis EC, Tsimogiannis KE, Pappas-Gogos G, et al. Different pain scores in single transumbilical incision laparoscopic cholecystectomy versus classic laparoscopic cholecystectomy: a randomized controlled trial. Surg Endosc 2010; 24:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/26\">",
"      Love KM, Durham CA, Meara MP, et al. Single-incision laparoscopic cholecystectomy: a cost comparison. Surg Endosc 2011; 25:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/27\">",
"      Bucher P, Pugin F, Buchs NC, et al. Randomized clinical trial of laparoendoscopic single-site versus conventional laparoscopic cholecystectomy. Br J Surg 2011; 98:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/28\">",
"      Ma J, Cassera MA, Spaun GO, et al. Randomized controlled trial comparing single-port laparoscopic cholecystectomy and four-port laparoscopic cholecystectomy. Ann Surg 2011; 254:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/29\">",
"      Lirici MM, Califano AD, Angelini P, Corcione F. Laparo-endoscopic single site cholecystectomy versus standard laparoscopic cholecystectomy: results of a pilot randomized trial. Am J Surg 2011; 202:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/30\">",
"      Rattner D, Kalloo A, ASGE/SAGES Working Group. ASGE/SAGES Working Group on Natural Orifice Translumenal Endoscopic Surgery. October 2005. Surg Endosc 2006; 20:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/31\">",
"      Marescaux J, Dallemagne B, Perretta S, et al. Surgery without scars: report of transluminal cholecystectomy in a human being. Arch Surg 2007; 142:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/32\">",
"      Zornig C, Emmermann A, von Waldenfels HA, Mofid H. Laparoscopic cholecystectomy without visible scar: combined transvaginal and transumbilical approach. Endoscopy 2007; 39:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/33\">",
"      Zorr&oacute;n R, Filgueiras M, Maggioni LC, et al. NOTES. Transvaginal cholecystectomy: report of the first case. Surg Innov 2007; 14:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/34\">",
"      Avgerinos C, Kelgiorgi D, Touloumis Z, et al. One thousand laparoscopic cholecystectomies in a single surgical unit using the \"critical view of safety\" technique. J Gastrointest Surg 2009; 13:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/35\">",
"      Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg 1995; 180:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/36\">",
"      Stiegmann GV, Soper NJ, Filipi CJ, et al. Laparoscopic ultrasonography as compared with static or dynamic cholangiography at laparoscopic cholecystectomy. A prospective multicenter trial. Surg Endosc 1995; 9:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/37\">",
"      Machi J, Johnson JO, Deziel DJ, et al. The routine use of laparoscopic ultrasound decreases bile duct injury: a multicenter study. Surg Endosc 2009; 23:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/38\">",
"      Tonouchi H, Ohmori Y, Kobayashi M, Kusunoki M. Trocar site hernia. Arch Surg 2004; 139:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/39\">",
"      Poggio JL, Rowland CM, Gores GJ, et al. A comparison of laparoscopic and open cholecystectomy in patients with compensated cirrhosis and symptomatic gallstone disease. Surgery 2000; 127:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/40\">",
"      Guidelines for laparoscopic surgery during pregnancy. Surg Endosc 1998; 12:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/41\">",
"      Soper NJ, Hunter JG, Petrie RH. Laparoscopic cholecystectomy during pregnancy. Surg Endosc 1992; 6:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/42\">",
"      Kuy S, Roman SA, Desai R, Sosa JA. Outcomes following cholecystectomy in pregnant and nonpregnant women. Surgery 2009; 146:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/43\">",
"      Curet MJ. Special problems in laparoscopic surgery. Previous abdominal surgery, obesity, and pregnancy. Surg Clin North Am 2000; 80:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/44\">",
"      Simopoulos C, Botaitis S, Karayiannakis AJ, et al. The contribution of acute cholecystitis, obesity, and previous abdominal surgery on the outcome of laparoscopic cholecystectomy. Am Surg 2007; 73:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/45\">",
"      Mahmud S, Masaud M, Canna K, Nassar AH. Fundus-first laparoscopic cholecystectomy. Surg Endosc 2002; 16:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/46\">",
"      Philips JA, Lawes DA, Cook AJ, et al. The use of laparoscopic subtotal cholecystectomy for complicated cholelithiasis. Surg Endosc 2008; 22:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/47\">",
"      Beldi G, Gl&auml;ttli A. Laparoscopic subtotal cholecystectomy for severe cholecystitis. Surg Endosc 2003; 17:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/48\">",
"      Jones DB, Dunnegan DL, Soper NJ. The influence of intraoperative gallbladder perforation on long-term outcome after laparoscopic cholecystectomy. Surg Endosc 1995; 9:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/49\">",
"      Deziel DJ, Millikan KW, Economou SG, et al. Complications of laparoscopic cholecystectomy: a national survey of 4,292 hospitals and an analysis of 77,604 cases. Am J Surg 1993; 165:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/50\">",
"      Carlin CB, Kent RB Jr, Laws HL. Spilled gallstones--complications of abdominal-wall abscesses. Case report and review of the literature. Surg Endosc 1995; 9:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/51\">",
"      Horton M, Florence MG. Unusual abscess patterns following dropped gallstones during laparoscopic cholecystectomy. Am J Surg 1998; 175:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/52\">",
"      Zamir G, Lyass S, Pertsemlidis D, Katz B. The fate of the dropped gallstones during laparoscopic cholecystectomy. Surg Endosc 1999; 13:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/53\">",
"      Ishizawa T, Bandai Y, Kokudo N. Fluorescent cholangiography using indocyanine green for laparoscopic cholecystectomy: an initial experience. Arch Surg 2009; 144:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/54\">",
"      Pertsemlidis D, Barzilai A, Persemlidis DS, et al. Enhanced laparoscopic visualization of the extrahepatic bile duct with intravenous indocyanine green [abstract]. Am J Gastroenterol 1993; 88:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/55\">",
"      Curet MJ, Contreras M, Weber DM, Albrecht R. Laparoscopic cholecystectomy. Surg Endosc 2002; 16:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/56\">",
"      Jaunoo SS, Mohandas S, Almond LM. Postcholecystectomy syndrome (PCS). Int J Surg 2010; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/4/11338/abstract/57\">",
"      Girometti R, Brondani G, Cereser L, et al. Post-cholecystectomy syndrome: spectrum of biliary findings at magnetic resonance cholangiopancreatography. Br J Radiol 2010; 83:351.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3685 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11338=[""].join("\n");
var outline_f11_4_11338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TIMING OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Endoscopic retrograde cholangiopancreatography (ERCP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114901495\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114901628\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Safety checklist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H114901272\">",
"      Abdominal access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Conventional port placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H359875832\">",
"      - Single-site port approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H359875385\">",
"      - Natural orifice transluminal endoscopic surgery (NOTES)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Gallbladder exposure and dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dissection of the hepatocystic triangle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Critical view of safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Division of cystic artery and cystic duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Evaluation for choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Intraoperative cholangiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Laparoscopic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Dissection of gallbladder from liver bed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Gallbladder extraction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Gangrenous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Large cystic duct",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      INTRAOPERATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      ROUTINE POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      POSTOPERATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H689178094\">",
"      Postcholecystectomy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/3685\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3685|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/63/28657\" title=\"diagnostic image 1\">",
"      Normal intraoperative cholangiogram after cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3685|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/19/25910\" title=\"figure 1\">",
"      Laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/14/34018\" title=\"figure 2\">",
"      Port placement for laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/17/21778\" title=\"figure 3\">",
"      Alternative port placement for cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/3/25649\" title=\"figure 4\">",
"      Critical view of safety in laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3685|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/19/14643\" title=\"picture 1\">",
"      Single incision laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3685|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/17/28955\" title=\"table 1\">",
"      Indications and contraindications laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 2\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/21/7517\" title=\"table 3\">",
"      Empiric therapy gram negatives and anaerobes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6742?source=related_link\">",
"      Acalculous cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43399?source=related_link\">",
"      Adjuvant treatment for localized, potentially resectable gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=related_link\">",
"      Approach to the patient with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6440?source=related_link\">",
"      Common bile duct exploration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22905?source=related_link\">",
"      Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13209?source=related_link\">",
"      Gallbladder polyps and cholesterolosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=related_link\">",
"      Intercurrent hepatobiliary disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=related_link\">",
"      Laparoscopic surgery in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=related_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2103?source=related_link\">",
"      Natural orifice transluminal endoscopic surgery (NOTES)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36489?source=related_link\">",
"      Open cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39668?source=related_link\">",
"      Porcelain gallbladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6232?source=related_link\">",
"      Repair of common bile duct injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=related_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/35/7738?source=related_link\">",
"      Treatment of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21992?source=related_link\">",
"      Ultrasonography of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_4_11339="Efficacy of Rx for anovulation";
var content_f11_4_11339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approximate ovulation and pregnancy rates following ovulation induction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ovulation rate percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cumulative pregnancy rate",
"percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clomiphene",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonadotropins",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulsatile GnRH*",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dopamine agonists&bull;",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *&nbsp;Indicated only for women with hypogonadotropic hypogonadal anovulation (WHO class 1).",
"     <br>",
"      &bull; Indicated only for women with hyperprolactinemia-induced anovulation.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11339=[""].join("\n");
var outline_f11_4_11339=null;
var title_f11_4_11340="ATPIII LDL goals";
var content_f11_4_11340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ATP III LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Risk category",
"      </td>",
"      <td class=\"subtitle1\">",
"       LDL-cholesterol goal",
"      </td>",
"      <td class=\"subtitle1\">",
"       LDL-cholesterol level at which to initiate therapeutic lifestyle changes",
"      </td>",
"      <td class=\"subtitle1\">",
"       LDL-cholesterol level at which to consider drug therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coronary heart disease (CHD) or CHD risk equivalent (10-year risk &gt;20 percent)*",
"      </td>",
"      <td>",
"       &lt;100 mg/dL (2.58 mmol/L)",
"      </td>",
"      <td>",
"       &ge;100 mg/dL (2.58 mmol/L)",
"      </td>",
"      <td>",
"       &ge;130 mg/dL (3.36 mmol/L); drug optional at 100 to 129 mg/dL (2.58 to 3.33 mmol/L)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2 or more risk factors (10-year risk &le;20 percent)&Delta;",
"      </td>",
"      <td>",
"       &le;130 mg/dL (3.36 mmol/L)",
"      </td>",
"      <td>",
"       &ge;130 mg/dL (3.36 mmol/L)",
"      </td>",
"      <td>",
"       10-year risk 10 to 20 percent: &gt;130 mg/dL (3.36 mmol/L) 10-year risk &lt;10 percent: &ge;160 mg/dL (4.13 mmol/L)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0 to 1 risk factor&loz;",
"      </td>",
"      <td>",
"       &le;160 mg/dL (4.13 mmol/L)",
"      </td>",
"      <td>",
"       &ge;160 mg/dL (4.13 mmol/L)",
"      </td>",
"      <td>",
"       &ge;190 mg/dL (4.91 mmol/L); LDL-cholesterol lowering drug optional at 160 to 189 mg/dL (4.13 to 4.88 mmol/L)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * CHD risk equivalents defined in text. 10-year risk defined by Framingham risk score (see text).",
"     <br>",
"      &bull; Some authorities recommend use of LDL-cholesterol lowering drugs in this category if LDL-cholesterol &lt;100 mg/dL (2.58 mmol/L) cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-cholesterol (eg, nicotinic acid or fibrate). Clinical judgement may also call for deferring drug therapy in this subcategory.",
"      <br>",
"       &Delta; Risk factors that modify LDL-cholesterol goals include cigarette smoking; hypertension (BP 140/90 mmHg or on antihypertensive medication); low HDL-cholesterol (&lt;40 mg/dL [1.03 mmol/L]); family history of premature CHD (CHD in male first degree relative &lt;55 years or CHD in female first degree relative &lt;65 years); age (men 45 years; women 55 years). HDL-cholesterol 60 mg/dL (1.55 mmol/L) counts as a negative risk factor; its presence removes one risk factor from the total count.",
"       <br>",
"        &loz; Almost all people with 0 to 1 risk factor have a 10-year risk &lt;10 percent; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Adult Treatment Panel III at file://www.nhlbi.nih.gov/.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11340=[""].join("\n");
var outline_f11_4_11340=null;
var title_f11_4_11341="Cost utility league table";
var content_f11_4_11341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cost-utility league table (example data for cost-effectiveness analyses)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"2\">",
"        <strong>",
"         <em>",
"          For illustration purposes only",
"         </em>",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Medical intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incremental cost-effectiveness ratio",
"        <br/>",
"        ($ per discounted quality-adjusted life year gained)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Screening siblings and children of patients with hereditary hemochromatosis",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        $508-$3665",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low-molecular weight heparin for deep vein thrombosis",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        $7820",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colorectal cancer screening",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        $10,000-$25,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin for secondary prevention of coronary heart disease",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        $11,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexible sigmoidoscopy evaluation of rectal bleeding in young persons",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        $11,461",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combination antiretroviral therapy",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        $23,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiofrequency ablation for supraventricular tachycardia",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        $27,900",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intensive glycemic control for type 2 diabetes",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td>",
"        $41,384",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Center hemodialysis",
"        <sup>",
"         [9]",
"        </sup>",
"       </td>",
"       <td>",
"        $55,000-$80,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged hospitalization following uncomplicated acute MI",
"        <sup>",
"         [10]",
"        </sup>",
"       </td>",
"       <td>",
"        $105,629",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nissen fundoplication",
"        <sup>",
"         [11]",
"        </sup>",
"       </td>",
"       <td>",
"        &gt;$1,000,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern Med 2000; 132:1.",
"      </li>",
"      <li>",
"       Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999; 130:789.",
"      </li>",
"      <li>",
"       Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:96.",
"      </li>",
"      <li>",
"       Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002; 346:1800.",
"      </li>",
"      <li>",
"       Lewis JD, Brown A, Localio AR, Schwartz JS. Initial evaluation of rectal bleeding in young persons: a cost-effectiveness analysis. Ann Intern Med 2002; 136:99.",
"      </li>",
"      <li>",
"       Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824.",
"      </li>",
"      <li>",
"       Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med 2000; 133:864.",
"      </li>",
"      <li>",
"       The CDCDC-eG. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287:2542.",
"      </li>",
"      <li>",
"       Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002; 22:417.",
"      </li>",
"      <li>",
"       Newby LK, Eisenstein EL, Califf RM, et al. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med 2000; 342:749.",
"      </li>",
"      <li>",
"       Heudebert GR, Marks R, Wilcox CM, Centor RM. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 1997; 112:1078.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11341=[""].join("\n");
var outline_f11_4_11341=null;
var title_f11_4_11342="MRI wrist septic arthritis child";
var content_f11_4_11342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Imaging septic arthritis in sickle cell disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 167px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an MRI of the wrist in a 4.5-year-old boy with sickle cell disease and septic arthritis. The red arrow shows an area of fluid collection, while the blue arrows show areas of diffuse bone marrow signal changes involving the metacarpal bones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     MRI courtesy of Dr. Sheldon L Kaplan, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11342=[""].join("\n");
var outline_f11_4_11342=null;
var title_f11_4_11343="Management of treatment interruptions";
var content_f11_4_11343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Management of treatment interruptions for patients with tuberculosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 368px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients who were initially AFB smear-positive should receive additional therapy.",
"     <br>",
"      &bull; Recheck smears and cultures (if positive, check drug susceptibility results). Start DOT if not already being used.",
"      <br>",
"       &Delta; If repeat culture is positive, restart four-drug regimen while waiting for drug susceptibility results. If repeat culture is negative, continue therapy to complete regimen within 9 months of original start date.",
"       <br>",
"        &loz; If repeat culture is positive, continue four-drug regimen while waiting for drug susceptibility results. If repeat culture is negative, consider stopping therapy if patient has received a total of 9 months of therapy.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Blumberg, HM, Burman, WJ, Chaisson, RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603. Official Journal of the American Thoracic Society. Copyright &copy;2003 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_4_11343=[""].join("\n");
var outline_f11_4_11343=null;
